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ABSTRACT 
Jennifer Renée Kulzer: Molecular and Biological Mechanisms  
of the ARAP1 Type 2 Diabetes Locus 
(Under the direction of Karen L. Mohlke) 
 
Genome-wide association studies (GWASs) have identified more than 70 loci associated 
with type 2 diabetes (T2D), but for most, the underlying causal variants, associated genes, and 
functional mechanisms remain unknown.  At a T2D- and fasting-proinsulin-associated locus on 
11q13.4, we have identified a functional regulatory DNA variant, a candidate target gene, and 
plausible underlying molecular and biological mechanisms.  We confirmed the existence of a 
single major association signal between fasting proinsulin and noncoding variants  
(p = 7.4 × 10-50).  Measurement of allele-specific mRNA levels in human pancreatic islet 
samples heterozygous for rs11603334 showed that the T2D-risk increasing and proinsulin-
decreasing allele (C) is associated with increased ARAP1 expression (p < 0.02).  By performing 
transcriptional reporter assays in rodent pancreatic beta cell lines, we determined that the C allele 
of rs11603334, located at the ARAP1 P1 promoter, exhibits 2-fold higher transcriptional activity 
than T allele (p < 0.0001).  Electrophoretic mobility shift assays demonstrated decreased binding 
of pancreatic beta cell transcriptional regulator PAX6 to the rs11603334 C allele.  Collectively, 
these data suggest that the T2D-risk allele of rs11603334 could abrogate binding of a complex 
containing PAX6 and thus lead to increased P1 promoter activity and ARAP1 expression in 
human pancreatic islets.  We went on to determine that the ARAP1 protein isoform 
corresponding to ARAP1 mRNA transcripts transcribed from P1 is a major isoform present in 
iv 
human islets, and that adenoviral overexpression of this ARAP1 isoform in intact human islets 
led to decreased levels of glucose-stimulated proinsulin secretion (p = 0.02).  Using G-LISA 
GTPase activity assays, we also determined that, through the activity of its ARF-GAP domain, 
increased ARAP1 expression in human islets decreases the levels of ARF6-GTP (p = 0.02), a 
known regulator of glucose-stimulated insulin secretion in the beta cell.  We also showed that 
ARAP1 and ARF6 partially colocalize in the cytoplasm of dispersed human beta cells.  
Altogether, this body of evidence demonstrates a connected set of molecular and biological 
mechanisms that may explain GWAS association of the ARAP1 locus with proinsulin and T2D. 
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CHAPTER 1: INTRODUCTION 
 
Genome-wide association studies (GWAS) have identified over 70 genomic locations, or 
loci, associated with type 2 diabetes (T2D), but for most of these loci, the underlying functional 
mechanisms remain unknown.  Naturally occurring human genetic variants at a T2D GWAS 
locus on chromosome 11 containing ARAP1, PDE2A, STARD10, ATG16L2, and FCHSD2 is 
associated with T2D risk (p = 1.4 x 10-22) and decreased proinsulin levels (p = 3.2 x 10-102).1,2  At 
this ‘ARAP1’ locus, robust statistical association of twenty frequently co-inherited single 
nucleotide polymorphism (SNP) variants with T2D, proinsulin, and several additional glycemic 
traits have been reported in independent populations,1–4 providing high confidence that there 
exist unknown underlying biological explanations worthy of exploration.  The aims of my 
research were to identify the functional variant(s) and gene(s) at the ARAP1 locus and determine 
how the gene(s) play a role in proinsulin secretion, the most strongly associated trait, from pancreatic 
islets.  Determining the molecular and biological mechanisms underlying high-confidence GWAS 
loci like ARAP1 will uncover new biological pathways involved in diabetes, improve our 
understanding of the disease, and may lead to the discovery of novel therapeutic targets. 
 
Overview of Type 2 Diabetes (T2D) and Insulin 
Diabetes is a severe and expensive disease, affecting 11.3% of Americans age 20 years or 
older.5  It is the seventh leading cause of death in the U.S., costing $116 billion each year in direct 
2 
medical expenses.  The overwhelming majority (90-95%) of those with diabetes have T2D.   
T2D develops when glucose levels in the bloodstream are chronically elevated due to 
insufficient regulation by insulin.  Insulin is a peptide hormone that is secreted from pancreatic beta 
cells in response to increased levels of glucose and other nutrients present in the circulation after 
eating.  Insulin’s precursor protein, proinsulin, is translated in the rough endoplasmic reticulum and 
transported to the Golgi apparatus for modifications and sorting.  In the trans-Golgi, proinsulin is 
packaged into granules, where it is converted to mature insulin.6,7  There, enzymes cleave each 
proinsulin molecule to produce one molecule each of insulin and C-peptide.  Upon exposure of the 
beta cell to glucose, the mature insulin-containing granules fuse with the plasma membrane and 
exocytose their contents.  This is called the regulated release pathway, accounting for greater than 
99% of the insulin and proinsulin secreted from beta cells.8  Insulin signals many bodily tissues, such 
as liver, muscle, and adipose, to clear the glucose from the blood and use some of it for immediate 
energy while storing the rest as glycogen and fat for later use.  In individuals with T2D, this process 
is defective due to 1) inefficient insulin signaling in liver, muscle, and adipose, commonly referred to 
as “insulin resistance,” and 2) inadequate insulin secretion by the pancreas. 
Insulin resistance can develop slowly and be present for many years before glucose levels 
rise and diabetes develops.  During this time, the pancreas produces more insulin to compensate for 
insulin resistance in an attempt to maintain glucose homeostasis.  For many with insulin resistance, 
the pancreas does this quite successfully and diabetes never develops.  However, for some with 
insulin resistance, the pancreatic beta cells progressively lose their ability to secrete enough insulin, 
leading to a rise in blood glucose levels (hyperglycemia).  Since chronically elevated blood glucose 
causes complications, and evidence of sustained hyperglycemia is used clinically to diagnose T2D, 
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the declining ability of beta cells to secrete adequate amounts of insulin often marks the onset of 
disease. 
Poorly managed diabetes results in chronic hyperglycemia, which is damaging to blood 
vessels and nerves and can lead to complications in several highly vascularized organs.  Diabetes is 
the primary cause of adult blindness, kidney failure, and leg and foot amputations not resulting from 
trauma.5  It is also a major cause of painful peripheral neuropathies and male impotence.  
Macrovascular complications include 2-4 fold increased risk5 of heart disease death and stroke.  
Simply having diabetes, without any prior evidence of coronary heart disease (i.e., myocardial 
infarction, angina, abnormal electrocardiogram changes indicating ischemia), increases risk of death 
from a coronary event to the same extent as the risk faced by non-diabetics who have already shown 
signs of coronary heart disease.9  
The intricate biological mechanisms causing insulin resistance and impaired insulin secretion 
are still not well understood, despite several decades of research.  However, recent major advances in 
the field of genetics, including mapping of the human genome and discovering the extent of human 
genetic variation through deep-sequencing, provide an exceptional opportunity to pose new questions 
about the nature of genetic contribution to diabetes risk.  Research thoroughly examining the 
biological reasons why some individuals are more likely to develop T2D than others will illuminate 
novel pathways to explore for potential medical interventions and cures. 
 
Genetics of T2D 
T2D is a complex trait: its inheritance is influenced by both the environment and the 
contributions of many genes, each exerting a small individual effect.  Obesity is well known to be a 
major risk factor for the development of T2D; over 80% of persons with T2D are overweight or 
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obese.10  Even so, many who are overweight or obese do not become diabetic, and many others 
develop T2D even though they are lean.  This can be partly explained by the strong genetic 
component of T2D.  Population studies in the U.S.11 and Finland12 reported proband concordance in 
monozygotic twins to be 29-58% and 34%, respectively, and concordance increases with age.  In 
dizygotic twins, proband concordance was 14-17% and 16%, compared to population prevalences of 
5.7% and 3.3%, respectively. 
T2D is variably penetrant and has high genetic heterogeneity; many individual genetic loci 
associated with T2D have low penetrance and small effect sizes.  Although the disease symptoms 
manifest as one common disorder, the inheritance pattern does not fit a simple Mendelian model.  
However, on a molecular level, individual T2D-associated variants may act additively, such that risk 
for disease rises with each additional risk allele one carries. 
To systematically identify genetic loci associated with T2D risk, human geneticists have 
performed genome-wide association studies.1,13–15  GWAS is a powerful, unbiased, population-based 
method that usually uses additive modeling of common variants to discover novel loci statistically 
associated with a trait.  To date, over 70 loci associated with T2D have been identified through 
GWAS; the first 50 identified were estimated to explain about 10% of the inheritance.1  For many of 
the loci, the underlying variant(s) and gene(s) contributing to T2D risk remain unknown. 
 
Multiple Trait Associations at the ARAP1 Locus 
 The ARAP1 locus is robustly associated with T2D (p = 1.4 x 10-22)1 and has the strongest 
association with fasting proinsulin of all loci across the genome (p = 3.2 x 10-102).2  The most strongly 
associated ‘index’ SNPs are the same for both traits, implying that a shared set of functional 
mechanisms may underlie both associations.  These index SNPs, rs1552224 and rs11603334, are 
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located 113 bp apart within the 5’ untranslated region (UTR) of the short RefSeq (Reference 
Sequence) isoform of ARAP1 (ARAP1∆SAM).  These SNPs are always inherited together; they are in 
perfect linkage disequilibrium (LD; r2=1, European ancestry (EUR) population, 1000 Genomes Phase 
1).  All other SNPs inherited in a similar pattern (r2 > 0.8) with rs1552224 and rs11603334 are non-
coding.  The six genes closest to the association signal are ARAP1, STARD10, PDE2A, ATG16L2, 
FCHSD2, and mir-139. 
The index SNPs are also associated with additional glycemic traits (Table 1), including 
partially processed (‘split’) proinsulin, measures of insulin secretion such as the insulinogenic index, 
and insulin 30 min into an oral glucose tolerance test (OGTT).  Evidence of associations with several 
traits more clearly linked to insulin secretion than to insulin resistance suggests that the ARAP1 locus 
may influence T2D risk by altering pancreatic beta cell function. 
 
 
Notably, the T2D-risk increasing alleles for the index SNPs are the major alleles (rs11603334, C, 
minor allele frequency (MAF) = .13, CEU).  According to the Hardy-Weinberg formula, 76% of 
Caucasians (CEU) are predicted to be homozygous for the T2D-risk increasing allele, 23% are T2D-
Table 1. The Index SNPs at the ARAP1 Locus Are Associated with Multiple Glycemic 
Traits 
Trait p-value Effect Size n 
Direction of Effect 
rs11603334 
Ref. 
T2D-Risk 
Allele (C) 
Non-Risk 
Allele (T) 
Type 2 Diabetes 1.4 x 10-22 1.14 (OR) 101,290 - - 1 
Fasting Intact Proinsulin 3.2 x 10-102 -0.0928 (β) 26,599 Decreased Increased 2 
32,33-Split Proinsulin 1.2 x 10-25 -0.146 (β) 6,343 Decreased Increased 2 
Insulinogenic Index 2 x 10-6 -6.92 % 5,529 Decreased Increased 3 
30 min OGTT Insulin 0.001 -4.19 % 5,529 Decreased Increased 3 
30 min OGTT Glucose 2 x 10-5 1.97 % 5,529 Increased Decreased 3 
Fasting Glucose 1.20 x 10-4 0.0193 (β) 46,263 Increased Decreased 1 
Fasting Insulin 0.015 ‐0.0126 (β) 38,413 Decreased Increased 1 
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risk allele carriers, and only 2% are homozygous for the non-risk allele.  From the opposite 
perspective, individuals homozygous for the non-risk allele may also be considered to be “protected” 
from the increased risk of T2D conferred by rs11603334 C allele carrier status that is inherited in 
98% of Caucasians. 
 
Genes at the ARAP1 Locus 
ARAP1, STARD10, PDE2A, ATG16L2, and FCHSD2 are all expressed in human pancreas, 
islets, and flow-sorted beta cells.1,2,16,17  None of these genes can be clearly implicated in T2D based 
on what has been reported in the literature to date, so observations linking any of these genes to T2D 
biology will be novel.  ARAP1 (ARF-GAP with RHO-GAP domain, ankyrin repeat and PH 
domain 1) is a GTPase activating protein (GAP) that activates ADP-ribosylation factor (ARF) and 
Ras homolog (RHO) family GTPases, which regulate Golgi transport, membrane trafficking, and 
actin cytoskeleton dynamics.18  STARD10 binds and transfers phospholipids between membranes.19  
PDE2A is a cyclic nucleotide phosphodiesterase which degrades second messengers cGMP and 
cAMP.20  ATG16L2 shares sequence homology with ATG16, which is required for autophagy in 
yeast.21  FCHSD2 is named after its FCH and SH3 protein domains, and stimulates F-actin assembly 
in vitro.22,23  Mir-139 downregulates FOXO1 in mouse neonatal hepatocytes.24  
Although rs1552224 has been reported previously as an expression quantitative trait locus 
(eQTL) for STARD10 expression in blood (p = 8.6 x 10-7),1 liver (p = 1.79 x 10-5) and omental 
adipose tissue (p = 1.21 x 10-6),25 the importance of these associations to T2D is unclear.  The top 
SNP (rs519790, p =2.7 x 10-24) associated with STARD10 expression in blood is in low LD  
(r2 = 0.04) with rs1552224, indicating that the association signals representing T2D risk and 
STARD10 expression are probably not the same. 
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ARAP1 Protein Structure, Function, and Substrates 
ARAP1 may be the strongest candidate gene because the index SNPs lie within one of its 
alternative 5’UTRs, which is used by two out of three RefSeq isoforms.  Sequence homology 
predicts all three RefSeq protein isoforms of ARAP1 (NP_056057, NP_001128662, and 
NP_001035207) to contain one ARF-GAP domain, one RHO-GAP domain, one Ras-association 
(RA) domain, and five pleckstrin homology (PH) domains.26–29  GAP domains catalyze the 
guanosine triphosphate (GTP) hydrolysis activity of small GTPases.  GTP-bound forms of GTPases 
such as ARF and RHO are considered to be active because they bind to effectors, while guanosine 
diphosphate (GDP)-bound forms are mostly inactive.  ARF and RHO GTPases help regulate a 
variety of cellular processes, including vesicle trafficking and actin cytoskeleton reorganization.  RA 
domains bind GTPases.  PH domains can bind phosphoinositides (PI) in lipid membranes, and they 
can also interact with GTP-bound small GTPases.30  Alternatively spliced out exons in the ARF-GAP 
domain and in the C-terminal PH domain of ARAP1 RefSeq isoform NP_001128662 create 
differences in these domains. 
The longest isoform of ARAP1, NP_001035207, which does not contain the index SNPs, has 
an additional sterile alpha motif (SAM) domain at its alternative 5’ end, as do homologs ARAP2 and 
ARAP3.  SAM domains interact with other proteins to facilitate many biological functions.31  In 
contrast to the shorter isoform (ARAP1∆SAM), the long isoform of ARAP1 does not catalyze 
ARF6-GTP hydrolysis, suggesting that the SAM domain may function as a negative regulator.32  
ARAP2 additionally differs from the long isoform of ARAP1 and from ARAP3 in that it contains an 
R>Q substitution at a catalytic residue of the RHO-GAP domain and lacks RHO-GAP activity.18,33  
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The ARAPs are the only known mammalian proteins containing both ARF-GAP and RHO-GAP 
domains. 
Though ARAP1 messenger RNA (mRNA) is expressed ubiquitously, ARAP1 protein 
expression and localization may be more variable.16–18  Endogenous ARAP1 protein localizes near 
the Golgi in resting HeLa cells18,34 and relocates to the cytoplasm and at the plasma membrane in 
spreading HeLa cells and NIH3T3 mouse fibroblasts.18  A detailed study in Hela cells demonstrates 
that endogenous ARAP1 is positioned at the trans Golgi and with recycling endosomes, 
multivesicular bodies, and lysosomes.35  Overexpressed ARAP1 is present throughout the cytoplasm 
in HeLa32,35 and NCTC immortalized human keratinocytes.36  Upon cell stimulation with either 
epidermal growth factor (EGF)34 or TNF-related apoptosis inducing ligand36, endogenous and/or 
overexpressed ARAP1 relocates to foci along the plasma membrane containing the corresponding 
receptors.  The PH domains also play an important role in ARAP1’s cellular localization.  Each PH 
domain has varying binding affinities to phosphorylated PI in vitro.  Treatment of NRK cells with  
PI-3 kinase inhibitors shifts ARAP1’s cellular distribution towards the Golgi, while PI-4 kinase 
inhibitors shift ARAP1’s cellular distribution towards the endosomal compartment.35  
ARAP1 plays a role in cytoskeletal reorganization18 and in the endocytosis and trafficking of 
certain receptors.  Conflicting reports suggest that overexpression35 and/or knockdown34 of ARAP1 
in HeLa cells leads to increased association of EGF and EGF receptor with early endosomes, 
increased EGF receptor degradation and reduced activation of the downstream Erk pathway.  ARAP1 
catalyzes GTP hydrolysis for ARF GTP-binding proteins ARF1, ARF5, and ARF6 in vitro18 and for 
ARF6 but not ARF1 in BHK cells.32  In vitro and in BHK cells, a R338K substitution in the  
ARF-GAP domain substantially decreases hydrolysis of GTP-bound ARF1 and ARF6, respectively.  
The RHO-GAP domain is not required for ARF-GAP activity.  However, in vitro ARF-GAP activity 
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is dependent on the presence of phosphorylated PI; PI 3,4,5 triphosphate (PI(3,4,5)P3) is most 
stimulatory, followed by PI(3,4)P2.  ARAP1 also catalyzes in vitro GTP hydrolysis for RHO 
GTPases RHOA and CDC42, while a R753K substitution in ARAP1’s RHO-GAP domain decreases 
CDC42 GTPase activity.18  Over-expressed ARAP1 catalyzes CDC42 GTPase activity in 293T 
cells.18  
ARAP1 has been demonstrated to regulate GTP hydrolysis in vitro for at least five  
GTP-binding proteins: ARF1, ARF5, ARF6, CDC42, and RHOA.18  The literature suggests plausible 
biological roles in insulin secretion for four of these. ARF1 might be involved early in the process of 
secretion as it is known to regulate transport between the endoplasmic reticulum and Golgi by 
recruiting coat proteins that allow vesicle budding when bound to GTP.37  ARF5 associates with the 
Golgi apparatus38 and may be involved in regulated secretion.  ARF5-GDP binds to calcium-
dependent activator protein for secretion 1 (CAPS1), a protein involved in secretion of dense core 
vesicles, in mouse cerebellum lysates.39  This interaction is required for proper KCl-stimulated 
release of a secretory protein called chromogranin A from the PC12 rat adrenal medulla cell line.39  
ARF6 localizes to the plasma membrane and is well known to regulate both clathrin-dependent and 
independent endocytosis as well as membrane recycling, and may play a role in regulated secretion 
for certain cell types.37,38  ARF6 is activated upon glucose stimulation in 832/13 cells, and cells 
expressing a dominant negative ARF6 mutant show reduced glucose-stimulated insulin secretion.40  
MIN6 cells expressing the same ARF6 mutant have reduced glucose- and K+-stimulated insulin 
secretion.41  CDC42 is important for glucose-stimulated insulin secretion in MIN6 cells and for the 
second phase of insulin secretion in mouse islets.42  Both ARF6 and CDC42 become activated within 
3 minutes of glucose stimulation.40,42  CDC42 also plays a role in insulin-stimulated glucose 
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transporter 4 (GLUT4) translocation to the plasma membrane of 3T3-L1 mouse adipocytes.43  
RHOA regulates actin polymerization;44 however, a potential role for it in insulin secretion is unclear. 
In this dissertation, I investigate and describe functional molecular and biological 
mechanisms that may underlie the genome-wide association of the 11q13.4 ARAP1 locus with 
proinsulin levels and T2D.  In Chapter 2, I identify a plausible functional regulatory variant, 
rs11603334, and demonstrate its allelic effects on expression of a specific isoform of ARAP1.  In 
Chapter 3, I characterize localization and isoform expression of ARAP1 protein in the human 
pancreatic islet, demonstrate that the ARAP1 isoform implicated in Chapter 2 can regulate glucose-
stimulated islet secretion of proinsulin, and show that this ARAP1 isoform regulates ARF6-GTP 
levels in an ARF-GAP domain-dependent manner.  Finally, in Chapter 4, I discuss the implications of 
my research results and consider the possible role of altered ARAP1 expression in T2D risk. 
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CHAPTER 2: A COMMON FUNCTIONAL REGULATORY VARIANT AT A TYPE 2 
DIABETES LOCUS UPREGULATES ARAP1 EXPRESSION IN THE PANCREATIC 
BETA CELLi,ii 
 
Introduction 
Genome-wide association studies have identified more than 70 loci associated with type 2 
diabetes [MIM 125853]1,45–52 and 10 loci associated with fasting proinsulin levels.2,53  A locus at 
11q13.4 near ARAP1 [MIM 606646], PDE2A [MIM 602658], STARD10, ATG16L2, and 
FCHSD2 is strongly associated with T2D (rs1552224, p = 1.4  10-22),1 fasting proinsulin 
(rs11603334, p = 3.2  10-102),2 and 32,33-split proinsulin (rs11603334, p = 1.2  10-25).2  This locus 
is also nominally associated with insulinogenic index (rs1552224, p = 2  10-6) and both insulin  
(p = 0.001) and glucose (p = 2  10-5) levels at 30 minutes during an oral glucose tolerance test.3  The 
clustering of multiple phenotypic associations related to proinsulin processing and insulin secretory 
response during an oral glucose challenge suggests that the affected target gene(s) may play a role in 
pancreatic beta cell function.  Currently, the functional DNA variant(s), the affected gene(s), and the 
underlying molecular genetic mechanism(s) contributing to these associations are unknown. 
                                                          
iThis chapter previously appeared as an article in the American Journal of Human Genetics.  The original citation is 
as follows: Kulzer JR, Stitzel ML, Morken MA, Huyghe JR, Fuchsberger C, Kuusisto J, Laakso M, Boehnke M, 
Collins FS, Mohlke KL. “A common functional regulatory variant at a type 2 diabetes locus upregulates ARAP1 
expression in the pancreatic beta cell.” American Journal of Human Genetics, 94(2):186-97 (2014). 
 
iiJennifer Kulzer designed, performed, and analyzed the allelic expression imbalance assays, dual-luciferase 
transcriptional reporter assays, and electromobility shift assays; prioritized regulatory variants and transcription 
factors; and wrote the manuscript.  Coauthors designed, performed, and analyzed the OGTT clinical studies, 
genotyping, fine-mapping and conditional analyses and allelic expression imbalance assays; and reviewed and 
edited the manuscript. 
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SNPs rs1552224 and rs11603334 are in perfect LD with each other (r2 = 1, EUR) and are 
located within the first exon and 5’UTR of ARAP1 RefSeq isoforms NM_015242 and 
NM_001135190, at +305 nt and +418 nt, respectively, from the transcription start site (TSS) at 72.11 
Mb (hg18) on chromosome 11.  A third ARAP1 RefSeq isoform, NM_001040118, is expressed from 
an alternative promoter and TSS located at 72.14 Mb.  We designate the promoter at 72.11 Mb as P1 
and the promoter at 72.14 Mb as P2. 
We hypothesized that functional variant(s) at this locus may be in high LD (r2 ≥ 0.8) with 
rs1552224 and rs11603334.  None of the variants in high LD with these SNPs are within gene coding 
regions where they could alter protein function, suggesting that functional common SNP(s) at this 
locus may influence gene regulation.  Genes within the LD region containing rs1552224 and 
rs11603334 have reported expression in human pancreas, islets, and flow-sorted beta cells;1 
however, islet expression of ATG16L2, FCHSD2, and PDE2A may not be above background.16,17,54  
None of these genes have been demonstrated to play roles in insulin processing or secretion.  
ARAP1 is a GTPase activating protein (GAP) that activates ARF and RHO family GTPases, which 
regulate membrane trafficking and actin cytoskeleton reorganization.18  STARD10 binds and 
transfers membrane phospholipids.19  PDE2A is a cyclic nucleotide phosphodiesterase, degrading 
second messengers cGMP and cAMP.20  ATG16L2 shares sequence homology with ATG16, a 
protein required for autophagy in yeast.21  FCHSD2 is named for its FCH and SH3 protein 
domains.22  
Here, we show data supporting rs11603334 as a functional variant regulating ARAP1 
expression.  Dense fine-mapping data and conditional analyses support a single association 
signal.  We demonstrate that the T2D-risk allele (C) of rs11603334 is associated with increased 
ARAP1 transcript levels in primary human pancreatic islets, disrupts binding of a protein complex 
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containing transcriptional regulators, and increases transcriptional activity at the ARAP1 P1 
promoter.  These data suggest that increased ARAP1 P1 promoter activity and ARAP1 expression 
may be molecular consequences of the T2D-associated variants in this region. 
 
Materials and Methods 
Study Population and Phenotypes 
We included 8,635 Finnish men without diabetes and not taking diabetes medication 
(mean age 57.2 years (range 45-74 years); mean body mass index (BMI) 26.8 kg/m2 (range  
16.2-51.6 kg/m2); fasting plasma glucose levels < 7 mmol/l and 2-hour oral glucose tolerance test 
plasma glucose levels < 11.1 mmol/l) from the population-based Metabolic Syndrome in Men 
(METSIM) study55 in the proinsulin association analyses.  Fasting plasma-specific proinsulin 
(Human Proinsulin RIA kit, Linco Research, St. Charles, MO; no cross-reaction with insulin or 
C-peptide) and fasting insulin (ADVIA Centaur Insulin IRI, 02230141, Siemens Medical 
Solutions Diagnostics, Tarrytown, NY; minimal cross-reaction with proinsulin or C-peptide) 
were measured by immunoassay.  For the T2D association analyses, 1,389 T2D cases and 5,748 
normoglycemic controls were included.  The study was approved by the ethics committee of the 
University of Kuopio and Kuopio University Hospital and informed consent was obtained from 
all study participants. 
 
Genotyping 
Samples were genotyped with the Illumina HumanOmniExpress BeadChip.  In sum, 
681,789 autosomal SNPs passed quality control (Hardy-Weinberg equilibrium, HWE  
p ≥ 1  10–6 in the total sample; call frequency ≥ 0.97).  The same samples were previously  
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genotyped using the Illumina HumanExome BeadChip,53 which focuses on protein-altering 
variants selected from more than 12,000 exome and genome sequences. 
 
Imputation and Reference Panel 
A two-step imputation strategy was used, wherein samples were pre-phased using 
ShapeIT version 256 before genotypes were imputed with Minimac.57  To increase imputation 
quality, 5,474 haplotypes from the 2,737 Central-Northern European samples sequenced within 
the Genetics of Type 2 Diabetes (GoT2D) study were used as a reference panel (C. Fuchsberger 
et al., and J. Flannick, C. Fuchsberger, et al., 2012, Am. Soc. Hum. Genet., abstracts). 
 
Fine-Mapping and Conditional Analysis 
SNP associations with log-transformed fasting plasma proinsulin levels were tested 
assuming an additive genetic model, using a linear mixed model with an empirical kinship 
matrix to account for relatedness as implemented in EMMAX,58 and with adjustment for age, 
BMI, and log-transformed fasting plasma insulin.  Both raw residuals and rank-based inverse-
normal transformed residuals were analyzed to assess robustness of rare-variant associations 
with outliers.  Genotyped variants with minor allele count (MAC) ≥ 5 (MAF ~0.03%); HWE  
p ≥ 1  10-6; and imputed variants with imputation quality score Rsq > 0.3 and MAF ≥ 0.03% 
were included in the analyses.  To identify additional independent signals in the region, 
conditional analyses were performed on previously reported lead SNP rs11603334 or on our 
fine-mapped lead SNP rs7109575, using allele count (genotyped variants) or allelic dosage 
(imputed variants) as a covariate in the model.  SNP associations with T2D were tested similarly 
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but with adjustment for age only.  Kang et al.58  describe and motivate the use of a linear mixed 
model for analysis of a binary outcome. 
 
Allelic Expression Imbalance (AEI) 
Human islets from non-diabetic organ donors were obtained from the National Disease 
Research Interchange (NDRI) and the Islet Cell Resource/Integrated Islet Distribution Program 
(ICR/IIDP).  DNA and RNA were obtained from 87 primary human pancreatic islet samples using 
the PureGene (DNA) or RNAeasy kits (RNA) (Qiagen, Gaithersburg, MD).  Reverse transcription of 
the RNA was performed using the Superscript III first-strand synthesis system (Life Technologies, 
Grand Island, NY).  Common, transcribed SNPs (minor allele frequency ≥ 0.1) with the highest LD 
values with previously reported lead SNPs rs11603334 and rs1552224 were selected for testing 
allelic expression of ARAP1, STARD10, PDE2A, and FCHSD2 (Table 2).  LD plots including the 
transcribed SNPs were created using the HapMap genome browser (Figure 7).59  High quality 
genomic DNA (gDNA) and mRNA were available for five islet samples heterozygous for 
rs11603334 and rs1552224; one additional high quality heterozygous sample each was available 
for mRNA only or gDNA only.  For each transcribed SNP, the relative proportions of each allele 
comprising the gDNA and complementary DNA (cDNA) were quantified using Sequenom iPLEX 
matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry-
based genotyping (Sequenom, San Diego, CA).  Primers were designed using MassARRAY 
(Sequenom) (Table 3).  The primers were designed within a single exon to avoid amplicon size 
differences between gDNA and cDNA, except for rs2291289, which is located near an 
exon/intron boundary.  To control for assay variation, the proportions of each SNP allele 
measured in the cDNA were analyzed relative to measurements taken in the gDNA.  Data are 
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reported as percent of total gDNA or cDNA containing a given transcribed SNP allele.  
Statistical significance of differences in allelic representation was determined based on LD 
scenarios as previously described.60  Briefly, two-sided t tests were used when the transcribed 
SNP and lead SNPs were in perfect LD (D’ = 1.0, r2 = 1.0), or when the transcribed SNP and 
lead SNPs were in intermediate LD with low pairwise correlation (D’ ≈ 1.0, r2 < 0.2).  For all t 
tests, F tests were first used to determine equal or unequal variance.  Non-parametric Wilcoxon 
pair-wise tests were used instead of t tests when gDNA or cDNA measurement data were not 
normally distributed.  One-sided F tests were used when the transcribed SNP and lead SNPs 
were in low LD (D’ < 0.2, r2 < 0.2). 
 
Regulatory Variant Selection 
All known variants in high LD (r2 ≥ 0.8, EUR) with rs11603334 and rs1552224 were 
identified using EUR data from Phase 1 of the 1000 Genomes project.61  Variants were prioritized 
based on location relative to regions of potential regulatory function, marked by the following: open 
chromatin in primary human pancreatic islets detected by formaldehyde-assisted isolation of 
regulatory elements (FAIRE)62 and DNase hypersensitivity,63 accessible chromatin in primary 
human pancreatic islets detected by chromatin immunoprecipitation (ChIP)-seq for active histone H3 
lysine methylation or acetylation modifications (H3K4me3, H3K4me1, and H3K9ac) as reported in 
the Human Epigenome Atlas,64 and transcription factor binding in Encyclopedia of DNA Elements 
(ENCODE) tissues or cell lines detected by ChIP-seq.65  
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Cell Culture 
MIN6 mouse insulinoma beta cell line66 was grown in Dulbecco's Modified Eagle's 
medium (DMEM) culture medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum (FBS), 1 mM sodium pyruvate, and 100 μM 2-mercaptoethanol.  INS-1-derived 832/13 rat 
insulinoma beta cell line67 (a gift from C.B. Newgard, Duke University, Durham, NC) was 
grown in Roswell Park Memorial Institute (RPMI) 1640 culture medium (Corning Cellgro, 
Mannassas, VA) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 
mM Hepes, and 0.05 mM 2-mercaptoethanol.  Both lines were maintained at 37°C and 5% CO2.  
One day prior to transfection, MIN6 cells were seeded at a density of 200,000 cells per well on 
24-well plates.  832/13 cells were seeded at a density of 300,000 cells per well on 24-well plates, 
or 150,000 cells per well on 48-well plates. 
 
Dual-Luciferase Transcriptional Reporter Assay 
Genomic regions including variant positions were polymerase chain reaction (PCR)-
amplified from human gDNA using 5 PRIME Mastermix (5 PRIME, Inc., Gaithersburg, MD) or 
Expand High Fidelity PCR System (Roche, Indianapolis, IN) with the primers listed in Table 4.  
Amplified DNA was subcloned using XhoI, KpnI, and/or NheI restriction enzymes and T4 DNA 
Ligase (New England Biolabs, Inc., Ipswich, MA) into the multiple cloning site upstream of the 
firefly luciferase gene in the pGL4.10 promoterless vector (Promega, Madison, WI).  Site-
directed mutagenesis was performed using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent, Santa Clara, CA) and the primers listed in Table 4.  For each construct, two to ten 
independent clones were selected.  The fidelity and genotype of each gDNA construct was 
verified by sequencing.  Equal amounts, between 600 and 800 ng, of each gDNA construct or 
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empty pGL4.10 promoterless vector were co-transfected with 80 ng of Renilla luciferase vector 
using Lipofectamine 2000 (Life Technologies, Grand Island, NY) into duplicate wells of MIN6 
or 832/13 cells.  Transfected cells were incubated at 37°C and 5% CO2 overnight and the 
transfection media was replaced with fresh culture media after 24 hours.  Forty-eight hours post-
transfection, cell lysates were collected and assayed for luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega).  Firefly luciferase activity was normalized to that 
of Renilla luciferase to control for differences in transfection efficiency.  Normalized data are 
reported as the fold change (± standard deviation, SD) in relative activity compared to that of the 
empty pGL4.10 promoterless vector control.  Two-sided t tests were used to compare luciferase 
activity between genotypes or haplotypes.  F tests were used to determine equal or unequal 
variance.  Two-way analysis of variance (ANOVA) was used for simultaneous comparisons of 
haplotypes resulting from two independently tested SNPs. 
 
Electrophoretic Mobility Shift Assay (EMSA) and Transcription Factor Prediction 
Four sets of complementary 21-mer oligonucleotides centered on rs11603334 (C/T) or 
rs1552224 (T/G) were generated, containing either of the two alternate alleles, both with and 
without biotin end-labeling (Integrated DNA Technologies, Coralville, IA).  Each set was 
annealed to create double-stranded oligos by incubating 50 pmol of each single-stranded oligo 
together in buffer containing 10 mM Tris, 1 mM EDTA, and 50 mM NaCl at 95°C for 5 minutes, 
followed by gradual cooling to 4°C.  Double-stranded oligo sequences are specified in Table 5.  
Nuclear protein lysates were extracted from MIN6 and 832/13 cell pellets with NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific, Waltham, MA) and protein 
concentrations were determined using Pierce BCA Protein Assay (Thermo Scientific).  EMSAs 
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were carried out with the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) according to 
the manufacturer’s instructions.  Each protein-DNA binding reaction contained 1X binding buffer, 1 
μg poly(dIdC), 4 μg nuclear protein lysates, and 100 fmol biotin-labeled double-stranded oligo in 20 
μl total reaction volume.  For samples demonstrating DNA competition, 60-fold excess unlabeled 
double-stranded oligo was pre-incubated with nuclear protein lysates in the reaction mixture for 20 
minutes before the addition of biotin-labeled oligo.  For EMSA reactions with supershift, 4 μg 
antibody was added to the final reaction mixture and the samples were incubated for an additional 30 
minutes.  JASPAR,68 TRANSFAC,69 CONSITE,70 PWMSCAN,71 and Tfsitescan72 were used to 
computationally predict transcription factors that may differentially bind at rs11603334 by 
contrasting the predictions and/or scores generated for each SNP allele.  Transcription factor 
ChIP-seq data for the region overlapping rs11603334 were obtained from the ENCODE 
project.65  Antibody to PAX6 (PRB-278P) was purchased from Covance (Princeton, NJ).  
Antibodies to PAX4 (M-45X, sc-98942X) and AP-2β (H-87X, sc-8976X) were purchased from 
Santa Cruz Biotechnology (Dallas, TX).  Antibodies to HIF1α (MA1-516) and HIF1β (MA1-515) 
were purchased from Thermo Scientific.  Additional antibodies to the following factors were also 
purchased and tested for supershift: YY1 (39071, 39345), Active Motif (Carlsbad, CA); NFIC 
(ab86570), Abcam (Cambridge, UK); AP-2α (C-18, sc-184X), YY1 (C-20, sc-281X; H-414, sc-
1703X), MAX (C-124, sc-765X), p53 (DO-1, sc-126X), OCT3/4 (C-10, sc-5279X), SP1 (E-3, sc-
17824X), USF-1 (C-20, sc-229X), EGR-1 (C-19, sc-189X), RXRα (D-20, sc-553X), E4BP4 (V-19, 
sc-9549X), PDX1 (N-18, sc-14662X), CEBPβ (C-19, sc-150X), CUX1 (C-20, sc-6327X), and p300 
(C-20, sc-585X), Santa Cruz Biotechnology.  Protein-DNA complexes were separated by 
electrophoresis on 6% DNA retardation gels (Life Technologies, Grand Island, NY) in 0.5X TBE 
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(Lonza, Rockland, ME), transferred to nylon membranes (Thermo Scientific), and UV cross-
linked before proceeding with chemiluminescent detection. 
 
Results 
Fine-Mapping of the 11q13.4 Locus Associated with Fasting Proinsulin and T2D 
To fine-map the fasting proinsulin association signal, we performed association analyses in 
8,635 Finnish subjects from the METSIM study using SNPs imputed from a reference panel of 
2,737 sequenced Central-Northern European individuals and SNPs directly genotyped on an 
exome array.53  The lead SNP was rs7109575 (p = 7.4  10-50; n = 8,635), a non-coding variant 
located at the ARAP1 P2 TSS (Figure 1, Table 6) and in high LD (r2 = 0.94) with previously 
reported lead proinsulin-associated SNP rs116033342 (p = 2.2  10-48; n = 8,630).  Conditional 
analyses using rs11603334 or rs7109575 as covariates largely attenuated the proinsulin 
association signal (all SNPs, p > 1.0  10-5; Figure 1, Figure 8, Table 6, and data not shown).  
One rare missense variant genotyped in a 1 Mb region on the exome array was associated  
(p < 0.05) with proinsulin after conditional analysis (rs202137453, MAF = 0.003, p = 0.015, 
pconditional-rs11603334 = 8.5 × 10
-5, Table 6).  Association with T2D using 1,389 case and 5,748 control 
subjects (rs7109575, p = 2.2  10-3; rs11603334, p = 3.6  10-3) was also attenuated after 
conditional analysis (p > 0.05; Table 6, Figure 9, and data not shown).  Taken together, fine-
mapping and conditional analyses provide evidence supporting a functional regulatory role for 
common variant(s) in high LD with rs7109575 and rs11603334. 
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Figure 1. Variants Associated with Proinsulin in the METSIM Study 
LocusZoom73 plots of fasting proinsulin association adjusted for age, BMI, and fasting insulin.  
The robust association with proinsulin levels (top panel: rs7109575, p = 7.4  10-50) is attenuated 
upon inclusion of rs11603334 as a covariate (bottom panel, only showing y axis to 10-20).  Each 
SNP is colored according to its LD (r2) with rs11603334. Genomic coordinates refer to hg18 
(UCSC Genome Browser). 
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The Proinsulin-Decreasing and T2D-Risk Alleles are Associated with Increased ARAP1 mRNA 
Levels in Primary Human Pancreatic Islets 
 
To determine if expression of ARAP1, STARD10, PDE2A, or FCHSD2 is associated with 
the T2D- and fasting proinsulin-associated lead SNPs, we evaluated allelic expression imbalance 
(AEI) in primary human pancreatic islets.  AEI maximizes sensitivity and power to detect modest 
cis-acting effects on mRNA expression through quantification of allele-specific transcript levels 
within heterozygous samples, thereby controlling for differential trans-acting and environmental 
exposures between individuals74 as well as differential sample purity and viability between islet 
preparations.75,76  The allelic composition of the total transcript levels for each gene was 
quantitatively determined with Sequenom MALDI-TOF mass spectrometry, a sensitive approach 
that conserves limited biological sample, and statistically analyzed relative to the allelic composition 
of the gDNA (Methods).  Located in the first exon and 5’UTR of ARAP1 isoforms transcribed 
from P1, previously reported lead SNPs rs11603334 and rs1552224 demonstrated AEI (Figure 
2).  In six samples heterozygous for rs11603334 and rs1552224, we observed ARAP1 expression 
differences of 7 to 12% between alleles.  For both SNPs, the T2D-risk alleles were associated with 
higher ARAP1 transcript levels (rs11603334, p = 0.0002; rs1552224, p = 0.015).  Due to lower LD 
between the lead SNPs and a third ARAP1 transcribed SNP located in a downstream exon, 
rs2291289 (r2 = 0.12, D’ = 1.0, rs11603334, EUR), only three samples were heterozygous for 
both rs2291289 and rs11603334 (Table 2).  The gDNA-to-cDNA comparison showed no AEI, 
while a comparison among cDNA samples showed the non-risk allele associated with modestly 
increased transcript levels (Figure 10A).  We also attempted to evaluate AEI for nearby genes 
containing transcribed SNPs in lower LD with rs11603334, using previously described statistical 
methods.60  We did not observe significant evidence of AEI for STARD10, PDE2A, or FCHSD2 
(Figure 10B-D and data not shown); zero to four samples were heterozygous for each transcribed 
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SNP and rs11603334 (Table 2).  Overall, these results suggest that one or more functional variants in 
high LD with rs11603334 and rs1552224 may increase the transcriptional activity or message 
stability of ARAP1 isoforms containing these SNPs. 
 
 
Figure 2. The T2D-Risk Alleles of rs11603334 and rs1552224 Are Associated with 
Increased ARAP1 Expression 
Allelic expression analysis in human pancreatic islet gDNA and cDNA from six donors each, 
including five matched pairs (matched pairs only: rs11603334, p = 0.0008; rs1552224, p = 0.06). 
The proportion of total gDNA and cDNA containing the T2D-risk alleles of rs11603334 (left) 
and rs1552224 (right) from heterozygous samples are quantified on the y axis.  The cDNA 
containing the T2D-risk allele was expressed 12.6% and 7.3% more than the cDNA containing 
the nonrisk allele in the rs11603334 and rs1552224 assays, respectively.  The p-values were 
calculated with a two-sided t test. 
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Candidate Regulatory Variants at the ARAP1 Promoters 
The originally identified lead SNPs rs11603334 and rs1552224 at the P1 promoter overlap 
ENCODE transcription factor binding sites within a region of open and accessible chromatin in 
human pancreatic islets that is marked by DNase hypersensitivity and active histone H3 lysine 
modifications H3K4me3 and H3K9ac (Figure 3 and Table 7).   The lead fine-mapped SNP in this 
study, rs7109575 (r2 = 0.94 with rs11603334, EUR), is located within an islet DNase hypersensitivity 
region and clustered transcription factor binding at the P2 promoter (Figure 11 and Table 7).  Among 
the 17 additional variants in high LD with rs11603334 (r2 ≥ 0.8, EUR; Table 7), rs77464186  
(r2 = 0.95 with rs11603334, EUR) is the next most promising functional candidate due to its location 
within a region of islet DNase hypersensitivity and clustered transcription factor binding in the first 
intron of ARAP1 isoforms transcribed from the P2 promoter (Figure 11 and Table 7). 
  
Table 2. Transcribed SNPs Used to Evaluate Allelic Expression Imbalance for ARAP1, 
STARD10, PDE2A, and FCHSD2 
Gene SNP Annotation 
Alleles 
Major/ 
Minor 
MAF 
LD with 
rs11603334 # Informative 
Heterozygotesb 
D’ r
2
 
ARAP1 rs11603334 5'UTR C/T .16 1 1 6 
ARAP1 rs1552224 5'UTR T/G .16 1 1 6 
ARAP1 rs2291289 Synonymous A/G .41 .94 .12 3 
STARD10 rs2291290 3'UTR A/G .11 1 .025 2 
STARD10 rs519790 5'UTR C/G .28 .97 .071 2 
PDE2A rs392565 Synonymous C/T .30 .011 .0053 4 
FCHSD2 rs76762469 3’UTR G/T .10 .18a .001a 0 
MAF, minor allele frequency; LD, linkage disequilibrium; UTR, untranslated region.  MAF, 
D’, and r2 data are estimated from EUR, 1000 Genomes Phase 1, except aCEU, 1000 
Genomes Pilot.  bOf 87 total human pancreatic islet samples. 
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Figure 3. SNPs rs11603334 and rs1552224 Are Located in a Region with Evidence of 
Regulatory Potential at the ARAP1 P1 Promoter at 72.11 Mb 
University of California Santa Cruz (UCSC) Genome Browser (hg18) diagram showing 
rs11603334 and rs1552224 situated at the ARAP1 P1 promoter and 18 additional variants in high 
LD (r2 ≥ 0.8).  ARAP1 is transcribed from right to left. SNPs rs11603334 and rs1552224 overlap 
regions of accessible chromatin in human pancreatic islets detected by H3K4me3 and H3K9ac 
ChIP-seq, are situated within or proximal to regions of open chromatin in human pancreatic 
islets detected by DNase hypersensitivity and FAIRE, and overlap binding sites for Pol2 and 
other transcription factors detected by ChIP-seq in several ENCODE cell lines (see also Table 7). 
The DNA sequences cloned for evaluating differential allelic transcriptional activity in the dual-
luciferase reporter assays are indicated. 
 
The rs11603334 T2D-Risk and Proinsulin-Decreasing Allele Increases Transcriptional Reporter 
Activity in Rodent Pancreatic Beta Cell Lines 
 
To interrogate allelic differences in transcriptional activity of rs11603334, rs1552224, 
rs7109575, and rs77464186, we cloned DNA sequences containing the T2D-risk (proinsulin-
decreasing) or non-risk (proinsulin-increasing) alleles into a promoterless luciferase vector and 
measured luciferase activity in the MIN6 mouse and 832/13 rat beta cell lines.  Due to the perfect LD 
and short distance between rs1552224 and rs11603334, we first tested them together as a haplotype 
in the context of the ARAP1 P1 promoter.  A 1,357-bp region of DNA, defined by DNase 
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hypersensitivity in human pancreatic islets and Pol2 binding in several other cell types (Figure 3), 
exhibited strong transcriptional activity compared to empty vector control in both MIN6 (Figure 4A) 
and 832/13 (Figure 4B).  The rs1552224 and rs11603334 T2D-risk haplotype (TC) demonstrated a 
two-fold increase in transcriptional activity compared to the non-risk haplotype (GT) in both MIN6 
(p < 0.0001) and 832/13 (p = 0.015), consistent with our finding that the T2D-risk alleles are 
associated with increased ARAP1 expression.  The 1,357-bp region also contained two short 
sequences of variable CT repeat length (CT6-10); however, the numbers of repeats at the two sites did 
not influence transcriptional activity (Figure 12A-B).  A narrower, 245-bp DNA region (Figure 3) 
containing only variants rs1552224 and rs11603334 also exhibited strong transcriptional activity 
compared to empty vector control (Figure 4C).  As observed with the 1,357-bp region, the two-SNP 
T2D-risk haplotype (TC) demonstrated a two-fold increase in transcriptional activity compared to the 
non-risk haplotype (GT) (p = 0.012).  To determine which of the SNPs is responsible for the 
haplotype effects on transcriptional activity at the P1 promoter, we used site-directed mutagenesis to 
synthetically create the alternate ‘missing’ haplotypes.  The T2D-risk C allele of rs11603334 
replicated the previously observed two-fold increase in transcriptional activity compared to the 
non-risk T allele (p < 0.0001), while the T2D-risk and non-risk alleles of rs1552224 (T/G) showed 
no significant difference (Figure 4D).  We did not observe evidence of allelic differences in 
transcriptional activity for either rs7109575 (Figure 4E) or rs77464186 (Figure 12C) near the P2 
promoter.  However, the 287-bp region of DNA surrounding rs7109575 increased transcriptional 
activity nine-fold compared to the empty control vector (p < 0.0001), consistent with promoter 
activity. 
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Figure 4. The T2D-Risk Allele, C, of rs11603334 Increases Transcriptional Activity of the 
ARAP1 P1 Promoter 
Transcriptional activity was evaluated with dual-luciferase reporter assays in the MIN6 mouse 
and 832/13 rat insulinoma β-cell lines 48 hr after transfection with recombinant vector 
containing selected regions of the human ARAP1 promoters cloned upstream of the luciferase 
gene.  (A) rs1552224 and rs11603334 evaluated as a haplotype in a 1,357 bp region at the 
ARAP1 P1 promoter in MIN6.  (B) rs1552224 and rs11603334 evaluated as a haplotype in the 
1,357 bp region in 832/13.  (C) rs1552224 and rs11603334 evaluated as a haplotype in a 
narrower 245 bp region at the ARAP1 P1 promoter in 832/13.  (D) Site-directed mutagenesis 
separated the effects of rs1552224 and rs11603334 in the 245 bp region in 832/13.  (E) 
rs7109575 evaluated in a 287 bp region at the ARAP1 P2 promoter in 832/13.  The p-values were 
calculated with a two-sided t test (A–C and E) or two-way ANOVA (D).  Data represent the 
mean of two to ten clones per allele ± SD.  A significance threshold of p < 0.05 was used.  NS, 
not significant. 
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Decreased in vitro Binding of PAX6 and PAX4 to the rs11603334 T2D-Risk and Proinsulin-
Decreasing Allele (C) 
 
We performed EMSAs using nuclear protein lysates extracted from MIN6 and 832/13 to 
evaluate differences in transcription factor binding to alleles of rs11603334 and rs1552224.  Multiple 
protein-DNA complexes were observed in the EMSAs, consistent with expectations for DNA within 
a promoter region (Figure 5 and Figure 13).  At least one protein complex was observed to bind 
specifically to the non-risk (T) allele of rs11603334 in MIN6 (Figure 5A, arrow).  DNA competition 
assays using excess unlabeled oligo containing the T allele reproducibly disrupted the protein-DNA 
complex more efficiently than excess unlabeled oligo containing the C allele, further supporting 
allelic differences in protein binding (Figure 5A, lanes 8 vs. 9; Figure 13A, lanes 7 vs. 8).  
Preferential protein binding to the T allele was also detected in 832/13 for a complex with similar 
mobility (Figure 13A, arrow).  To identify the differentially bound protein(s), we performed EMSAs 
with supershift using antibodies targeting transcription factors selected from those with 
computationally predicted or empirically determined (ChIP-seq) binding at rs11603334 (Materials 
and Methods).  Incubation with antibody targeting Pax6 partially disrupted the T allele-specific 
protein-DNA complex (Figure 5A, lane 10; Figure 5B, lane 8) and incubation with antibodies 
targeting both Pax6 and Pax4 fully disrupted the complex (Figure 5B, lane 10).  Among the other 
transcription factors tested with supershift assay, only AP-2β, Hif1α, and Hif1β were observed to 
bind to the 21-bp DNA sequence containing rs11603334; these proteins bound to both the C and T 
alleles with approximately equal affinity (Figure 13B-C, arrows).  We did not observe clear evidence 
of allele-specific protein binding to rs1552224 (Figure 13D). 
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Figure 5. The T2D-Risk Allele, C, of rs11603334 Disrupts Binding of Transcriptional 
Regulators PAX6 and PAX4 
Differential allelic protein-DNA binding was evaluated in vitro with EMSAs.  Biotin-labeled 21 
bp double-stranded DNA oligonucleotide centered on the reference (C) and alternate (T) alleles 
of rs11603334 was incubated with MIN6 nuclear lysate, and resulting protein-DNA complexes 
were separated by electrophoresis (A and B: lanes 2 and 7, respectively).  For the competition 
assays, EMSA reactions were incubated with 60-fold excess unlabeled DNA oligonucleotide 
containing either the T or C allele (A: lanes 8 and 9, respectively).  For the supershift assays, 
EMSA reactions were incubated with antibody targeting PAX6 (A: lane 10; B: lane 8), PAX4 
(B: lane 9), or both PAX6 and PAX4 (B: lane 10). 
 
Discussion 
For most T2D-associated loci identified through GWAS, the functional variants and affected 
genes are not known.  In this study, we identify a plausible functional regulatory variant, rs11603334, 
and demonstrate its allelic effects on expression of ARAP1, a gene at the 11q13.4 locus.  We 
provide evidence suggesting that the C allele of rs11603334 disrupts binding of transcriptional 
regulators and increases transcriptional activity at the ARAP1 P1 promoter, leading to higher 
ARAP1 expression in pancreatic islets.  Increased ARAP1 expression may be one molecular 
genetic contributor to T2D susceptibility. 
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We conducted association analyses using the densest set of variants to date, reporting 
rs7109575 as the lead fine-mapped SNP, and confirming the primary robust association with 
fasting proinsulin for previously reported lead SNPs rs11603334 and rs1552224.  Although not 
the most strongly associated SNP in this study, the association p-value for our proposed 
functional SNP rs11603334 (p = 2.2  10-48) was similar to that of rs7109575 (p = 7.4  10-50); 
sampling variability, missing genotypes, or imputation uncertainty may influence the relative p-
values.  Conditioning on either rs11603334 or rs7109575 attenuated the proinsulin association at 
this locus, consistent with a single signal at this locus and supporting the use of the r2 measure of 
LD to identify candidate functional SNPs.  Rare variants may also contribute to variation in 
proinsulin levels among carriers.  The variant that became more significant after adjusting for 
rs11603334 (rs202137453, STARD10 Pro196Ser) may be a true signal or a false positive among 
3,818 variants tested.  Further fine-mapping and conditional analyses using a larger T2D case-
control population will be needed to determine if other variants in the region also contribute to 
T2D risk. 
We demonstrate for the first time that the T2D-risk alleles of rs11603334 and rs1552224 are 
associated with increased ARAP1 mRNA expression in primary human pancreatic islets.  This 
finding was reproducibly evident with a small number of samples because AEI compares 
quantification of allele-specific mRNA levels within heterozygous individuals, thereby minimizing 
confounding effects such as inter-individual environmental exposures that can mask genotypic 
effects in eQTL studies.  We had the best power to detect association of rs11603334 and rs1552224 
with ARAP1 mRNA expression because the SNPs are located within an exon; this exon is specific to 
ARAP1 isoforms transcribed from the P1 promoter.  Previously, rs519790 was reported to be a strong 
eQTL for STARD10 in blood (p = 2.7  10-24);1 however, this SNP is in low LD with rs1552224 
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(r2 = 0.071, EUR), which shows only a modest, residual eQTL association with STARD10 (blood, p 
= 8.6  10-7; liver, p = 1.79  10-5; omental adipose tissue, p = 1.21  10-6).25  A nominal 
association between rs1552224 and ARAP1 (CENTD2) expression has been previously reported 
in T-cells (p = 0.019) in a direction consistent with our results.77,78  
In agreement with our finding that the T2D-risk alleles of rs11603334 and rs1552224 are 
associated with increased ARAP1 expression, our experiments using the transcriptional reporter 
assay show that the T2D-risk allele of rs11603334 upregulates transcriptional activity at the 
ARAP1 P1 promoter.  While transcriptional activity at a gene promoter may be expected, allelic 
differences in promoter activity cannot be predicted easily; functional assays are necessary to 
demonstrate allelic effects.  Among three tested variants situated at the ARAP1 P1 and P2 
promoters in this study, only rs11603334 demonstrated allelic effects on promoter activity.  
Taken together, the results from the AEI and transcriptional reporter assays implicate increased 
expression of ARAP1 isoforms containing rs11603334 and transcribed from the P1 promoter 
(NM_015242, NM_001135190) in T2D susceptibility. 
We show that the beta cell transcriptional regulator Pax6 preferentially binds to the 
mRNA-lowering (T) allele of rs11603334 in a protein-DNA complex that may also contain 
Pax4, suggesting a repressive role for one or both factors in transcription at the ARAP1 P1 
promoter (Figure 6).  Pax6 and Pax4 have similar binding sequences, although they bind DNA 
with different relative affinities.79–81  In the endocrine pancreas, Pax6 is often reported to 
function as a transcriptional activator, while Pax4 often functions as a repressor.  Pax4 has been 
shown to inhibit the transcriptional activity of co-expressed Pax6 in the HIT-T15 hamster beta 
cell line and in 293T cells, possibly through competition for DNA binding sites.80  Pax4 also 
represses basal transcriptional activity of the glucagon promoter in αTC1.9 and InR1G9 cells and 
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strongly represses Pax6-activated transcription of the both the glucagon81 and insulin 
promoters.82  However, repressive activity for human and mouse PAX6 has also been 
demonstrated for specific regulatory elements in other cell types.83–85  The observed inhibition of 
transcriptional activity for ARAP1 transcripts containing the rs11603334-T allele may be 
mediated by PAX4, PAX6, or both.  Human coding variants in PAX4 or PAX6 have been 
previously implicated in impaired glucose tolerance,86,87 early-onset diabetes,86,88 ketosis-prone 
diabetes,89 and proinsulin processing.90  Recently, genome-wide association signals for T2D have 
also been identified near PAX4 in East Asian45 and Chinese populations.91 
 
 
Figure 6. Proposed Model for PAX6 and PAX4 Repression of Transcriptional Activity at 
ARAP1 
PAX6 and PAX4 at rs11603334 in a complex with stronger binding to the ARAP1 mRNA-
decreasing T allele (B, T2D nonrisk) than to the mRNA-increasing C allele (A, T2D risk) 
suggests a role for one or both of these factors in repressing transcription at the ARAP1 P1 
promoter. Transcription factors HIF1α, HIF1β, and AP-2β bind both alleles. 
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Our results do not preclude the existence of additional functional genes, variants, and/or 
mechanisms at this locus.  Power to detect association of the lead SNPs with expression levels of 
STARD10, PDE2A, and FCHSD2 was limited due to small numbers of SNPs and samples 
informative for AEI.  Although 87 total islet samples were available, only six were heterozygous 
for rs11603334 and zero to four samples were informative for the STARD10, PDE2A, and FCHSD2 
assays.  We cannot exclude possible associations between rs11603334 and expression levels of these 
genes.  An assay to test AEI for all isoforms of ARAP1, using rs2291289, similarly was of limited 
utility due to the small number of heterozygous samples (n = 3) for this SNP and due to wide 
assay variance.  Moreover, ATG16L2 could not be tested using this approach because it does not 
contain any common transcribed SNPs.  Future analysis of a larger pancreatic islet expression 
dataset will be required to validate our findings for ARAP1 and assess allelic differences in gene 
expression for all other genes. 
  We chose to investigate the mechanisms underlying the set of variants most strongly 
associated with proinsulin and T2D following dense fine-mapping analyses.  We prioritized among 
highly significant non-coding variants based on their locations within regions of open chromatin in 
pancreatic islets and successfully identified a variant with allelic differences in transcriptional 
activity.  Variants located outside of these open chromatin regions may also be found to have 
regulatory function.  In addition, functional non-coding variants at this locus may regulate gene 
expression through allelic effects on splicing, message stability, or translational control.  Based on 
sequence, rs1552224 may create a splice site, and rs11603334-T creates a methionine codon 
upstream of the RefSeq start codon.  If used, this codon could potentially lead to attempted 
translation of a 90-nt upstream open reading frame, which could interfere with efficient translation of 
ARAP1.92  
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 Specific roles for ARAP1 in the process of proinsulin conversion and/or insulin secretion 
in the beta cell have not yet been reported. ARAP1 is located near both the Golgi and the plasma 
membrane in other cell types18,34–36 and has been demonstrated to regulate several members of 
the Arf and Rho small GTPase protein families in vitro and in cell culture.18,32  Of the reported 
substrates, both ARF6 and CDC42 have been shown to play a role in glucose-stimulated insulin 
secretion.40–42  Future work will address the effects of upregulated ARAP1 expression on 
proinsulin processing and insulin secretion in the pancreatic beta cell. Given that our data 
suggest that increased ARAP1 expression is associated with increased risk of T2D, ARAP1 
antagonists might hold important therapeutic potential. 
Identifying functional variants at T2D GWAS loci and elucidating mechanisms to explain 
how variants influence expression or function of target genes will help facilitate the discovery of 
biological gene candidates and novel pathways involved in disease pathology. This work 
contributes to a growing understanding of the molecular genetic architecture of T2D, provides a 
model of fine-mapping and experimental analyses that can be used for uncovering functional 
variants contributing to associations at GWAS loci, and paves the way for future research on the 
role of ARAP1 as a diabetes candidate gene in pancreatic islets. 
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Supplemental Figures and Tables 
 
 
Figure 7. Linkage Disequilibrium near PDE2A, ARAP1/CENTD2, STARD10, ATG16L2, 
and FCHSD2 
HapMap genome browser (hg18/NCBI 36) LD plot diagrams depicting D’ (black) and r2 (red) 
for CEU (data release 27 Phase II & III).  Six transcribed variants selected for AEI analysis are 
labeled near their relative genomic positions (blue).  In this figure, ARAP1 is labeled using its 
previous symbol, CENTD2. 
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Figure 8. All Variants Associated with Fasting Proinsulin in the METSIM Study 
LocusZoom plots of fasting proinsulin association adjusted for age, BMI and fasting insulin.  
The ~600 kb region containing PDE2A, ARAP1, STARD10, ATG16L2, and FCHSD2 is shown.  
The robust association with proinsulin levels (top panel: rs7109575, p = 7.4 x 10-50) is attenuated 
upon inclusion of rs11603334 as a covariate (bottom panel, only showing y-axis to 10-20).  Each 
SNP is colored according to its LD (r2) with rs11603334.  Genomic coordinates refer to hg18. 
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Figure 9. Variants Associated with T2D in the METSIM Study 
LocusZoom plots of T2D association in 1,389 case and 5,758 control subjects.  Conditional 
analysis on rs11603334 attenuated association of rs7109575 and LD proxies with T2D (top vs. 
bottom panels; bottom panel only showing y-axis to 10-4).  Each SNP is colored according to its 
LD (r2) with rs11603334.  Genomic coordinates refer to hg18. 
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Figure 10. Allelic Expression Analyses for ARAP1, STARD10 and PDE2A in Human 
Pancreatic Islet gDNA and cDNA 
The proportion of total gDNA and cDNA containing the G allele of transcribed ARAP1 SNP 
rs2291289 (A), the A allele of transcribed STARD10 SNP rs2291290 (B), the C allele of 
transcribed STARD10 SNP rs519790 (C), and the T allele of transcribed PDE2A SNP rs392565 
(D) are quantified on the y-axes.  All data points are heterozygous for the transcribed SNP.  The 
cDNA data are sub-divided by genotype of lead SNP rs11603334.  The p-values for panels A-D 
were calculated using two-sided t tests when the data were normally distributed.  F tests were 
performed to determine if variances were equal or unequal prior to performing each t test.  Non-
parametric Wilcoxon pair-wise tests were used in cases where the data were not normally 
distributed (A: comparisons of both gDNA and rs11603334 homozygous CC cDNA samples to 
heterozygous CT cDNA samples; B: comparison of homozygous cDNA samples to heterozygous 
cDNA samples; C: comparison of gDNA samples to heterozygous cDNA samples).  For PDE2A 
(D), a one-sided F test was additionally performed to compare the sample variance between 
cDNA heterozygous for rs11603334 to cDNA homozygous for rs11603334; result was non-
significant.  A significance level of p < 0.05 was used. 
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Figure 11. Variants with Regulatory Potential near the ARAP1 P2 Promoter 
UCSC genome browser (hg18) diagram showing six of twenty total variants in high LD (r2 ≥ 
0.8) with lead SNPs rs11603334 and rs1552224.  SNPs rs7109597 and rs77464186 overlap 
regions of open chromatin in human pancreatic islets detected by DNase hypersensitivity and 
other transcription factors detected by ChIP-seq across many ENCODE cell lines (Table 6).  
DNA sequences cloned to evaluate differential allelic transcriptional activity in the dual-
luciferase reporter assays are also shown. 
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Figure 12. ARAP1 Variants that Did Not Show Allelic Differences in Transcriptional 
Activity 
Transcriptional activity was evaluated using dual-luciferase reporter assays in the MIN6 and 
832/13 β-cell lines 48 hours after transfection with recombinant vector containing selected DNA 
regions cloned upstream of the luciferase gene.  A-B: Variable short CT repeats present within 
the 1357-bp region at the downstream ARAP1 promoter do not appear to influence 
transcriptional activity when tested in MIN6 (A) or 832/13 (B).  C: The 240-bp region containing 
rs77464186 generated less transcription of luciferase compared to empty vector in 832/13; 
however, the effect was not different between SNP alleles.  The p-values were calculated using a 
two-sided t test.  Data are represented as the mean of two to nine clones per allele ± standard 
deviation.  A significance level of p < 0.05 was used. 
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Figure 13. EMSAs Identify Additional Proteins Bound to rs11603334 
Differential allelic protein-DNA binding was evaluated in vitro using EMSA.  Biotin-labeled 21-
bp double-stranded DNA oligonucleotide centered on the reference or alternate alleles of 
rs11603334 (C/T) (A-C) or rs1552224 (T/G) (D) was incubated with MIN6 nuclear lysate (A: 
lanes 2 and 6; B: lanes 2 and 5; C: lanes 1 and 4) or 832/13 nuclear lysate (A: lanes 9 and 10; D: 
lanes 2, 4, 7, and 9) and the resulting protein-DNA complexes were separated by electrophoresis.  
For the competition assays (A and D), EMSA reactions were incubated with 60-fold (A) or 50-
fold (D) excess unlabeled DNA oligonucleotide containing rs11603334-T (A: lane 7), 
rs11603334-C (A: lane 8), rs1552224-T (D: lanes 3 and 5) or rs1552224-G (D: lanes 8 and 10).  
For the supershift assays (B-C), EMSA reactions were incubated with antibody targeting AP-2β 
(B: lanes 3 and 6), Hif1α (C: lanes 2 and 5), or Hif1β (C: lanes 3 and 6). 
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Table 3. Primers Used to Evaluate Allelic Expression Imbalance (AEI) 
Gene SNP Forward Reverse Extension 
Amplicon 
Length 
ARAP1 rs11603334 TGCGTATGCCCAAGAATGTC TGTTTGCGAGACCAGCCCAG ATGTCGTGTACCTGCCC 71 
ARAP1 rs1552224 GTCTGAGGCTGCGTTCTCTT TCCACAGTTATACACAGAAACAAACA GCCCAGGTATGGCTTTGC 129 
ARAP1 rs2291289 CCGCTCGCCCTGTATGTA CGCTGCAACTACGGAAACTG CACCTCCTTCGCTCCAC 
107 (cDNA) 
479 (gDNA) 
STARD10 rs2291290 GATCGTTTATTGGGGCTCTG CTTCAGGGACGGAGACAGG GGGCGGCGGCCGCTCCTGC 146 
STARD10 rs519790 GAAGAATTGGGAACAGGGACT GTCAGGTGATTGTAGATTGAGGA ATCCAACAAAGACACTGACC 247 
PDE2A rs392565 GATCAAAGATGTTGCAGCCG AGGCACCACTTTGCTCA GTGGGTGTTGAGGATGGC 61 
FCHSD2 rs76762469 TGTGGAAGAGATGTGCGTTAAT CACAAGGATGTGGCAAAGAT AGATCATGTTGGCTACATAA 227 
Only gene-specific sequences of the primers are shown.  All assays could be designed within one exon except rs2291289; this 
amplicon spans an intron in the gDNA. 
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Table 4. Primers Used to Generate Clones for Transcriptional Reporter Assays 
PCR amplification primers 
Variants Contained Insert Length Forward Reverse 
rs1552224, rs11603334 245 GTCCTTTCCTCCTGGACAGA CTGCGTATGCCCAAGAATGT 
rs1552224, rs11603334, 
(CT)x, (CT)y 
1357 GCCCAGAGATGCTGAGAAAC GGAAGAGGGAGGGATGAGAC 
rs7109575 287 ACTCCAGGACCGTGACTAGG GAAACTGCAGGCCAATGTG 
rs77464186 240 ACGACCATCACCCTCCAATA TCTCTACCACCCTCCCAATG 
Site-directed mutagenesis primers 
SNP Forward Reverse 
rs11603334 CGGGACCCAGGCTTGCATGGGCAGGTA TACCTGCCCATGCAAGCCTGGGTCCCG 
rs1552224 AAGACATAAATCACAGGGGCAAAGCCATACCTGGG CCAGGTATGGCTTTGCCCCTGTGATTTATGTCTT 
Only gene-specific sequences are shown.  Bold, underlined nucleotides indicate SNP position. 
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Table 5. Sequences Used to Generate Double-Stranded Oligos for Electrophoretic Mobility Shift Assay (EMSA) 
SNP Allele 5’Biotin labeling Forward Reverse 
rs11603334 
C Yes 5’Biotin-CAGGCTTGCACGGGCAGGTAC 5’Biotin-GTACCTGCCCGTGCAAGCCTG 
T Yes 5’Biotin-CAGGCTTGCATGGGCAGGTAC 5’Biotin-GTACCTGCCCATGCAAGCCTG 
C No CAGGCTTGCACGGGCAGGTAC GTACCTGCCCGTGCAAGCCTG 
T No CAGGCTTGCATGGGCAGGTAC GTACCTGCCCATGCAAGCCTG 
rs1552224 
T Yes 5’Biotin-AAATCACAGGTGCAAAGCCAT 5’Biotin-ATGGCTTTGCACCTGTGATTT 
G Yes 5’Biotin-AAATCACAGGGGCAAAGCCAT 5’Biotin-ATGGCTTTGCCCCTGTGATTT 
T No AAATCACAGGTGCAAAGCCAT ATGGCTTTGCACCTGTGATTT 
G No AAATCACAGGGGCAAAGCCAT ATGGCTTTGCCCCTGTGATTT 
Bold, underlined nucleotides indicate SNP position. 
 
  
  
 
4
5
 
Table 6. SNP Association with Fasting Proinsulin and Type 2 Diabetes in the METSIM Study 
SNP 
Chr11 
Position 
(hg18) 
Annotation EA NEA MAF 
 Fasting Proinsulin Association Type 2 Diabetes Association 
N 
Unconditioned Conditioned on rs11603334 Unconditioned Conditioned on rs11603334 
β (SE) p β (SE) p β (SE) p β (SE) p 
Lead SNPs (top 50 most significant) associated with fasting proinsulin 
rs7109575 72,141,083 Near TSS G A 0.250 8635 -0.270 (0.18) 7.43E-50 -0.395 (0.14) 5.91E-03 0.024 (0.01) 2.15E-03 0.104  (0.07) 1.21E-01 
rs11602873 72,138,410 Intron A T 0.250 8635 -0.270 (0.18) 9.95E-50 -0.387 (0.15) 8.79E-03 0.024 (0.01) 2.17E-03 0.109 (0.07) 1.16E-01 
rs77464186 72,138,046 Intron A C 0.250 8635 -0.270 (0.18) 1.02E-49 -0.386 (0.15) 9.13E-03 0.024 (0.01) 2.17E-03 0.109 (0.07) 1.16E-01 
rs11603349 72,138,342 Intron T C 0.250 8635 -0.270 (0.18) 1.02E-49 -0.386 (0.15) 9.15E-03 0.024 (0.01) 2.16E-03 0.110 (0.07) 1.14E-01 
rs74333814 72,135,135 Intron C T 0.249 8635 -0.270 (0.18) 1.70E-49 -0.579 (0.22) 7.06E-03 0.023 (0.01) 3.34E-03 0.046 (0.10) 6.55E-01 
rs7129793 72,133,533 Intron C T 0.249 8635 -0.269 (0.18) 2.30E-49 -0.582 (0.23) 1.11E-02 0.023 (0.01) 3.50E-03 0.028 (0.11) 7.99E-01 
rs1552224 72,110,746 5’UTR A C 0.253 8588 -0.268 (0.18) 1.06E-48 -0.275 (0.23) 2.26E-01 0.022 (0.01) 4.64E-03 -0.071 (0.09) 4.33E-01 
rs75896506 72,107,227 Intron G A 0.249 8635 -0.267 (0.18) 2.11E-48 -3.540 (3.44) 3.04E-01 0.023 (0.01) 3.62E-03 0.162 (1.40) 9.08E-01 
rs11603334 72,110,633 5’UTR G A 0.252 8630 -0.267 (0.18) 2.23E-48 - - 0.023 (0.01) 3.55E-03 - - 
rs76550717 72,105,820 Intron A G 0.247 8635 -0.262 (0.18) 2.90E-46 0.031 (0.10) 7.46E-01 0.023 (0.01) 3.72E-03 0.009 (0.04) 8.29E-01 
rs9667947 72,102,282 Intron T C 0.255 8635 -0.257 (0.18) 7.09E-46 0.044 (0.09) 6.22E-01 0.020 (0.01) 1.11E-02 -0.064 (0.04) 1.05E-01 
rs11605691 72,097,162 Intron C T 0.254 8635 -0.252 (0.18) 4.01E-44 -0.030 (0.05) 5.65E-01 0.022 (0.01) 5.36E-03 0.003 (0.02) 8.91E-01 
rs79430446 72,151,652 Intron G T 0.277 8635 -0.243 (0.17) 2.35E-43 -0.038 (0.05) 3.99E-01 0.022 (0.01) 3.00E-03 0.014 (0.02) 4.64E-01 
rs613937 72,152,487 Intron A G 0.277 8635 -0.242 (0.17) 3.69E-43 -0.035 (0.05) 4.41E-01 0.022 (0.01) 3.25E-03 0.013 (0.02) 5.03E-01 
rs77106637 72,155,968 Intron G A 0.277 8635 -0.242 (0.17) 3.85E-43 -0.037 (0.05) 4.12E-01 0.021 (0.01) 4.24E-03 0.009 (0.02) 6.43E-01 
rs117819392 72,192,151 Intergenic C T 0.304 8635 -0.213 (0.17) 9.51E-36 -0.033 (0.03) 2.61E-01 0.020 (0.01) 5.15E-03 0.009 (0.01) 4.57E-01 
rs145398037 72,199,790 Intergenic G C 0.304 8635 -0.213 (0.17) 9.61E-36 -0.034 (0.03) 2.42E-01 0.020 (0.01) 5.96E-03 0.008 (0.01) 5.04E-01 
rs1059000 72,182,620 Intergenic G C 0.303 8635 -0.213 (0.17) 1.01E-35 -0.032 (0.03) 2.62E-01 0.020 (0.01) 5.65E-03 0.009 (0.01) 4.89E-01 
rs73541184 72,105,796 Intron G A 0.315 8635 -0.212 (0.17) 1.05E-35 -0.014 (0.03) 6.47E-01 0.023 (0.01) 1.25E-03 0.019 (0.01) 1.49E-01 
rs76724404 72,189,169 Intergenic A C 0.304 8635 -0.213 (0.17) 1.18E-35 -0.032 (0.03) 2.76E-01 0.020 (0.01) 5.30E-03 0.009 (0.01) 4.67E-01 
rs3862791 72,178,650 Intron C T 0.303 8635 -0.213 (0.17) 1.24E-35 -0.031 (0.03) 2.85E-01 0.020 (0.01) 5.38E-03 0.009 (0.01) 4.74E-01 
rs139534838 72,184,528 Intergenic T C 0.304 8635 -0.212 (0.17) 3.13E-35 -0.029 (0.03) 3.05E-01 0.020 (0.01) 4.99E-03 0.010 (0.01) 4.43E-01 
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Table 6. SNP Association with Fasting Proinsulin and Type 2 Diabetes in the METSIM Study 
SNP 
Chr11 
Position 
(hg18) 
Annotation EA NEA MAF 
 Fasting Proinsulin Association Type 2 Diabetes Association 
N 
Unconditioned Conditioned on rs11603334 Unconditioned Conditioned on rs11603334 
β (SE) p β (SE) p β (SE) p β (SE) p 
rs11605166 72,347,425 Intron T C 0.306 8632 -0.212 (0.17) 4.15E-35 -0.030 (0.03) 2.93E-01 0.019 (0.01) 7.51E-03 0.007 (0.01) 5.79E-01 
rs11602858 72,292,717 Intron C G 0.294 8635 -0.210 (0.17) 2.70E-34 -0.038 (0.03) 1.64E-01 0.020 (0.01) 7.74E-03 0.007 (0.01) 5.23E-01 
rs2886599 72,398,919 Intron C A 0.295 8635 -0.210 (0.17) 3.48E-34 -0.037 (0.03) 1.75E-01 0.020 (0.01) 7.58E-03 0.008 (0.01) 5.17E-01 
rs185815472 72,297,508 Intron G A 0.295 8635 -0.209 (0.17) 6.76E-34 -0.035 (0.03) 1.99E-01 0.020 (0.01) 6.80E-03 0.008 (0.01) 4.79E-01 
rs7103836 72,152,219 Intron G C 0.336 8635 -0.200 (0.16) 1.80E-33 -0.014 (0.03) 6.24E-01 0.014 (0.01) 5.05E-02 -0.008 (0.01) 5.10E-01 
rs11602616 72,041,725 Intron T C 0.250 8635 -0.210 (0.18) 1.89E-30 -0.017 (0.03) 5.38E-01 0.023 (0.01) 3.53E-03 0.012 (0.01) 2.95E-01 
rs11604034 72,041,795 Intron G C 0.250 8635 -0.210 (0.18) 1.94E-30 -0.017 (0.03) 5.35E-01 0.023 (0.01) 3.77E-03 0.012 (0.01) 3.09E-01 
rs11601122 72,040,366 Intron A G 0.250 8635 -0.210 (0.18) 1.99E-30 -0.017 (0.03) 5.40E-01 0.023 (0.01) 3.47E-03 0.012 (0.01) 2.92E-01 
rs61895588 72,038,634 Intron A G 0.250 8635 -0.210 (0.18) 2.13E-30 -0.017 (0.03) 5.44E-01 0.023 (0.01) 3.44E-03 0.013 (0.01) 2.89E-01 
rs55765314 72,038,583 Intron C A 0.249 8635 -0.210 (0.18) 2.21E-30 -0.017 (0.03) 5.47E-01 0.023 (0.01) 3.43E-03 0.013 (0.01) 2.89E-01 
rs11600831 72,037,868 Intron C T 0.249 8635 -0.210 (0.18) 2.28E-30 -0.017 (0.03) 5.49E-01 0.023 (0.01) 3.40E-03 0.013 (0.01) 2.87E-01 
rs11604837 72,037,655 Intron G A 0.249 8635 -0.210 (0.18) 2.30E-30 -0.017 (0.03) 5.49E-01 0.023 (0.01) 3.39E-03 0.013 (0.01) 2.87E-01 
rs72962169 72,043,317 Intron C T 0.249 8635 -0.209 (0.18) 2.47E-30 -0.017 (0.03) 5.50E-01 0.024 (0.01) 2.49E-03 0.014 (0.01) 2.26E-01 
rs184654 72,042,053 Intron C G 0.249 8635 -0.209 (0.18) 3.71E-30 -0.015 (0.03) 5.91E-01 0.023 (0.01) 3.27E-03 0.013 (0.01) 2.78E-01 
rs11600585 72,405,488 Intron A G 0.340 8635 -0.183 (0.17) 4.06E-28 -0.009 (0.02) 7.06E-01 0.012 (0.01) 8.41E-02 -0.007 (0.01) 5.20E-01 
rs7109082 72,385,089 Intron A C 0.340 8635 -0.183 (0.17) 4.37E-28 -0.009 (0.02) 7.13E-01 0.012 (0.01) 8.31E-02 -0.007 (0.01) 5.25E-01 
rs3814730 72,233,201 Intron G A 0.332 8635 -0.181 (0.17) 2.64E-27 -0.016 (0.02) 4.84E-01 0.012 (0.01) 8.44E-02 -0.005 (0.01) 6.21E-01 
rs11603313 72,265,825 Intron G A 0.332 8635 -0.181 (0.17) 2.78E-27 -0.016 (0.02) 4.86E-01 0.012 (0.01) 8.88E-02 -0.005 (0.01) 5.98E-01 
rs17244499 72,307,594 Intron A G 0.332 8635 -0.181 (0.17) 2.94E-27 -0.016 (0.02) 4.88E-01 0.012 (0.01) 9.05E-02 -0.005 (0.01) 5.89E-01 
rs74439784 72,327,044 Intron A T 0.332 8635 -0.181 (0.17) 3.14E-27 -0.016 (0.02) 4.96E-01 0.012 (0.01) 9.04E-02 -0.005 (0.01) 5.89E-01 
rs12362059 72,091,332 Intron C T 0.353 8635 -0.177 (0.16) 7.68E-27 -0.002 (0.02) 9.30E-01 0.018 (0.01) 9.40E-03 0.007 (0.01) 4.99E-01 
rs12575364 72,086,837 Intron C T 0.352 8635 -0.176 (0.16) 9.90E-27 -0.001 (0.02) 9.78E-01 0.018 (0.01) 9.71E-03 0.007 (0.01) 5.13E-01 
rs61895574 72,025,636 Intron A T 0.228 8635 -0.201 (0.19) 1.10E-26 -0.021 (0.03) 4.16E-01 0.022 (0.01) 5.61E-03 0.011 (0.01) 3.09E-01 
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Table 6. SNP Association with Fasting Proinsulin and Type 2 Diabetes in the METSIM Study 
SNP 
Chr11 
Position 
(hg18) 
Annotation EA NEA MAF 
 Fasting Proinsulin Association Type 2 Diabetes Association 
N 
Unconditioned Conditioned on rs11603334 Unconditioned Conditioned on rs11603334 
β (SE) p β (SE) p β (SE) p β (SE) p 
rs56200889 72,085,703 
Missense 
ARAP1 
Gln802Glu 
G C 0.355 8621 -0.175 (0.16) 2.07E-26 0.002 (0.02) 9.48E-01 0.018 (0.01) 1.01E-02 0.007 (0.01) 5.25E-01 
rs10898864 72,083,098 Intron C T 0.360 8630 -0.172 (0.16) 7.61E-26 0.002 (0.02) 9.39E-01 0.016 (0.01) 1.89E-02 0.003 (0.01) 7.40E-01 
rs1783598 72,529,111 Intron T C 0.363 8635 -0.172 (0.16) 1.04E-25 -0.011 (0.02) 6.17E-01 0.016 (0.01) 2.24E-02 0.003 (0.01) 7.33E-01 
rs12292949 72,135,179 Intron C T 0.416 8635 -0.161 (0.16) 7.58E-24 -0.004 (0.02) 8.43E-01 0.011 (0.01) 1.14E-01 -0.005 (0.01) 5.89E-01 
rs67260737 72,135,844 Intron A G 0.415 8635 -0.160 (0.16) 1.56E-23 -0.003 (0.02) 8.99E-01 0.011 (0.01) 1.21E-01 -0.005 (0.01) 5.65E-01 
Top SNPs (p < 0.001) associated with fasting proinsulin after conditional analysis on rs11603334 
rs202137453 72,144,438 
Missense 
STARD10 
Pro196Ser 
G A 0.003 8621 0.319 (0.13) 1.54E-02 0.514 (0.13) 8.46E-05 0.062 2.72E-01 0.045 4.29E-01 
rs191209601 72,538,773 Intergenic T C 0.008 8635 -0.252 (0.10) 8.28E-03 -0.327 (0.09) 5.20E-04 -0.03 4.38E-01 -0.024 5.38E-01 
Additional genotyped nonsynonymous SNPs within 500 kb of rs11603334 
rs200273651 72,147,966 
Missense 
STARD10 
Ala106Thr 
C T 0.003 8621 0.189 (0.15) 1.99E-01 0.110 (0.15) 4.46E-01 0.025 6.98E-01 0.11 4.46E-01 
rs139124425 72,084,464 
Missense 
ARAP1 
Lys878Gln 
T G 0.005 8621 0.077 (0.11) 4.88E-01 0.007 (0.11) 9.49E-01 0.038 4.21E-01 0.007 9.49E-01 
rs143644813 72,083,694 
Missense 
ARAP1 
Val980Ile 
C T 0.001 8621 0.115 (0.23) 6.18E-01 0.089 (0.23) 6.97E-01 -0.07 5.14E-01 0.089 6.97E-01 
rs148377320 72,099,229 
Missense 
ARAP1 
Arg177His 
C T 0.020 8619 0.027 (0.06) 6.26E-01 -0.025 (0.06) 6.54E-01 -0.009 7.05E-01 -0.025 6.54E-01 
rs200662872 72,101,242 
Missense 
ARAP1 
Arg11Gln 
C T 0.000 8621 -0.216 (0.45) 6.29E-01 -0.109 (0.44) 8.04E-01 -0.16 4.71E-01 -0.109 8.04E-01 
rs149248685 72,099,211 
Missense 
ARAP1 
Ser183Phe 
G A 0.002 8621 0.059 (0.16) 7.05E-01 -0.012 (0.15) 9.39E-01 -0.036 5.80E-01 -0.012 9.39E-01 
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Table 6. SNP Association with Fasting Proinsulin and Type 2 Diabetes in the METSIM Study 
SNP 
Chr11 
Position 
(hg18) 
Annotation EA NEA MAF 
 Fasting Proinsulin Association Type 2 Diabetes Association 
N 
Unconditioned Conditioned on rs11603334 Unconditioned Conditioned on rs11603334 
β (SE) p β (SE) p β (SE) p β (SE) p 
rs150013910 72,091,645 
Missense 
ARAP1 
Ala462Val 
G A 0.001 8621 -0.083 (0.27) 7.58E-01 -0.120 (0.27) 6.53E-01 -0.109 3.33E-01 -0.12 6.53E-01 
rs143097446 71,761,685 
Missense 
CLPB 
Ser223Asn 
C T 0.006 8621 -0.023 (0.10) 8.17E-01 -0.095 (0.10) 3.26E-01 -0.024 5.65E-01 -0.095 3.26E-01 
rs341047 71,979,151 
Missense 
PDE2A 
Thr224Ile 
G A 0.158 8621 -0.004 (0.02) 8.44E-01 0.020 (0.02) 3.43E-01 -0.008 3.68E-01 0.02 3.43E-01 
rs150343959 71,682,301 
Missense 
CLPB 
Arg628Cys 
G A 0.001 8621 0.002 (0.30) 9.96E-01 -0.035 (0.30) 9.07E-01 -0.004 9.76E-01 -0.035 9.07E-01 
Evidence of SNP association with fasting proinsulin and type 2 diabetes in up to 8,635 non-diabetic individuals (fasting proinsulin), 
and in 1,389 cases and 5,748 normal glycemic controls (type 2 diabetes) from the METSIM study.  Beta coefficients (β) for proinsulin 
represent the change in inverse-normalized fasting proinsulin levels after adjustment for age, BMI, and fasting insulin.  Coefficients 
for type 2 diabetes are not directly interpretable; however, the signs indicate direction of effect, i.e., a positive sign indicates that the 
effect allele increases type 2 diabetes risk.  SNPs were either directly genotyped or imputed using a Central-Northern European 
reference panel (see Methods).  Call rates for directly genotyped SNPs exceeded 0.995 and were consistent with Hardy-Weinberg 
equilibrium (p > 0.01).  Imputation quality scores exceeded 0.990.  Positions on chromosome 11 are shown in hg18 coordinates; SNP 
names are from dbSNP 137.  SNPs in bold represent lead associated SNPs in this and previous association studies.  EA, effect allele 
(major allele); NEA, non-effect allele (minor allele); MAF, minor allele frequency. 
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Table 7. Twenty Variants in Strong Linkage Disequilibrium (r2 ≥ 0.8) with rs11603334 and rs1552224 
Variant 
Chr11 
Position 
(hg18) 
Genomic 
Annotation 
r2 a 
Open Chromatin 
in Human 
Pancreatic Isletsb 
Histone 
Modifications in 
Human Pancreatic 
Isletsc 
Transcription Factor Bindingb 
rs11605691 72,097,162 Intron of 
ARAP1 
0.85 - - - 
rs9667947 72,102,282 Intron of 
ARAP1 
0.88 - - - 
rs76550717 72,105,820 Intron of 
ARAP1 
0.99 - - - 
rs75896506 72,107,227 Intron of 
ARAP1 
1.0 - - EBF (GM12878) 
rs140717197d 72,107,445-7 Intron of 
ARAP1 
1.0 - - EBF (GM12878) 
rs11603334 72,110,633 
5’UTR near 
ARAP1  
P1 promoter 
1.0 DNase H3K9ac NFKB (GM12878); Ini1 (HeLa-S3) 
rs1552224 72,110,746 
5’UTR near 
ARAP1  
P1 promoter 
1.0 DNase H3K4me3, H3K9ac NFKB (GM12878) 
rs7129793 72,133,533 Intron of 
ARAP1 
0.92 - - - 
rs74333814 72,135,135 Intron of 
ARAP1 
0.95 - - - 
rs77464186 72,138,046 Intron of 
ARAP1 
0.95 DNase - 
HNF4α, RXRα, p300 (HepG2);  
JunD (HepG2, GM12878); NFKB, IRF4, BCL11A, BATF, 
POU2F2, SP1 (GM12878) 
rs11603349 72,138,342 Intron of 
ARAP1 
0.91 - - 
IRF4, POU2F2 (GM12878) 
rs11602873 72,138,410 Intron of 
ARAP1 
0.95 - - - 
rs142489578d 72,138,578-9 Intron of 
ARAP1 
0.95 - - - 
rs148527516d 72,139,460-1 Intron of 
ARAP1 
0.95 DNase - HEY1 (HepG2) 
rs7109575 72,141,083 
TSS near 
ARAP1  
P2 promoter 
0.94 DNase - 
Ini1, BAF155, BAF170, c-Myc (HeLa-S3); HNF4α, FOSL2, CEBPβ, 
Sin3Ak-20 (HepG2); PAX5, TCF12, SP1 (GM12878);  HEY1 
(HepG2, K562); PU.1(GM12891); TAF1 (HepG2, H1-hESC); MAX 
(HeLa-S3, K562, HUVEC); NFKB (GM15510, GM12891); USF-1 
(GM12878, HepG2, K562, A549) 
rs140130268d 72,148,564-7 Intron of 
STARD10 
0.92 - - 
- 
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Table 7. Twenty Variants in Strong Linkage Disequilibrium (r2 ≥ 0.8) with rs11603334 and rs1552224 
Variant 
Chr11 
Position 
(hg18) 
Genomic 
Annotation 
r2 a 
Open Chromatin 
in Human 
Pancreatic Isletsb 
Histone 
Modifications in 
Human Pancreatic 
Isletsc 
Transcription Factor Bindingb 
rs79430446 72,151,652 Intron of 
STARD10 
0.82 - - 
EBF, NFKB, PU.1, BCL3 (GM12878) 
rs140735484d 72,151,830 Intron of 
STARD10 
0.82 DNase H3K4me1 
EBF, NFKB, PU.1, BCL3, BCL11A, PAX5, TCF12 (GM12878) 
rs613937 72,152,487 Intron of 
STARD10 
0.80 - - PAX5, NFKB (GM12878) 
rs77106637 72,155,968 Intron of 
STARD10 
0.80 - - HNF4α (HepG2) 
SNPs in bold were evaluated for differential allelic transcriptional activity in this study.  TSS, transcription start site.   
awith rs11603334, EUR, 1000 Genomes, Phase 1.  bENCODE peak calls, hg18.  cHuman Epigenome Atlas, Release 1 (hg18); called 
if signal > ½ locus maximum.  dIndels 
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CHAPTER 3: ARAP1 REGULATES GLUCOSE-STIMULATED PROINSULIN 
SECRETION AND ARF6 GTPASE ACTIVITY IN HUMAN PANCREATIC ISLETSiii 
 
Introduction 
Previously, we presented evidence obtained from allelic expression imbalance and 
transcriptional reporter assays to suggest that the C allele of 5’UTR variant rs11603334, 
associated with decreased fasting proinsulin levels and increased risk of T2D, may function to 
upregulate expression of ARAP1 [MIM 606646] isoforms transcribed from the P1 promoter.93  
ARAP1 RefSeq isoforms NM_015242 and NM_001135190, corresponding to proteins NP_056057 
and NP_001128662, respectively, are transcribed from the P1 promoter and TSS located at 72.11 Mb 
(hg18) on chromosome 11.  ARAP1 protein isoform NP_001128662 differs from NP_056057 in that 
it contains an altered ARF-GAP domain and an altered C-terminal PH domain.  A third ARAP1 
RefSeq isoform, NM_001040118, corresponding to protein NP_001035207, is transcribed from the 
P2 promoter and TSS located at 72.14 Mb.  To date, ARAP1 protein localization and isoform 
expression in islets have not been characterized, and the biological role of the ARAP1 isoform we 
previously implicated as a functional candidate remains uninvestigated with respect to proinsulin and 
insulin secretion from the islet. 
ARAP1 (ARF-GAP with RHO-GAP domain, ankyrin repeat and PH domain 1) is a GTPase 
activating protein (GAP) that regulates the activity of ARF and RHO family GTPases by helping to 
                                                          
iiiJennifer Kulzer generated the adenoviral vectors; designed, performed and analyzed the glucose-stimulated 
secretion assays, ELISAs, G-LISA GTPase assays, and the immunofluorescence studies; designed and analyzed the 
Western blots.  Rani Vadlamudi performed Western blots, ELISAs, and G-LISA GTPase assays.  Rachel McMullan 
performed Western blots. 
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catalyze the ability of these GTPases to hydrolyze bound GTP to GDP.18  Since GTP-bound GTPases 
are usually considered ‘active’, while GDP-bound GTPases are usually considered ‘inactive’, GAP 
regulation typically leads to GTPase inactivation.  ARF and RHO family GTPases are known to 
regulate Golgi transport, membrane trafficking, and actin cytoskeleton dynamics, broad cellular 
processes of established importance to the transport, processing, and secretion of insulin in the 
pancreatic beta cell. 
Endogenous ARAP1 has been located near the Golgi in resting HeLa cells18,34 and has been 
observed to relocate to the cytoplasm and at the plasma membrane in spreading HeLa cells and 
NIH3T3 mouse fibroblasts;18 however, its location in the beta cell has not been examined.  In vitro or 
in cell culture using other cell types, others have demonstrated the ability of ARAP1 to help regulate 
GTP-to-GDP hydrolysis for five GTP-binding proteins: ARF1, ARF5, ARF6, CDC42, and 
RHOA;18,32 however, ARAP1 remains an understudied protein and a consensus for its ubiquitous 
activity on these substrates has not been reached.  Specifically, the GTPases regulated by ARAP1, if 
any, in the pancreatic beta cell and islet are unknown.  Of the reported ARAP1 ARF and RHO 
GTPase substrates in other cell types, ARF6 and CDC42, which are both activated within 3 minutes 
of glucose stimulation,40, 42 have been shown to play roles in glucose-stimulated insulin secretion.40–
42  However, their roles in proinsulin secreted have not been investigated.  Further, the GAPs that 
regulate ARF6 and CDC42 in in the beta cell or islet have not been identified.94 
Here, we characterize ARAP1 localization, activity, and isoform expression in human 
pancreatic islets, and we are the first to initiate experiments to test the hypothesis that increasing 
ARAP1 (NP_056057) expression in pancreatic beta cells might lead to decreased glucose-stimulated 
proinsulin and/or insulin secretion. 
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Materials and Methods 
Human Islets and Cell Culture 
Human islets from non-diabetic organ donors were obtained from the National Disease 
Research Interchange (NDRI) and the Islet Cell Resource/Integrated Islet Distribution Program 
(ICR/IIDP).  Upon arrival, islets were equilibrated for one hour at 37°C and 5% CO2 prior to being 
counted and partitioned for use.  Batches of islets that were used for DNA and protein lysate 
samples were rinsed with phosphate buffered saline (PBS), flash frozen in a dry ice and ethanol 
bath, and stored at -80°C until use.  Intact islets used for functional experiments were transferred 
to Connaught Medical Research Laboratories (CMRL) medium supplemented with 10% FBS, 2 
mM L-glutamine, 10 mM HEPES, 100 IU penicillin, and 100 μg/mL streptomycin, and cultured 
for 1-2 days at 37°C and 5% CO2 prior to use.  Islets used as dispersed cells for glucose-
stimulated insulin secretion experiments were cultured in 7 mM glucose RPMI medium 
supplemented with 10% FBS, 100 IU penicillin, and 100 μg/mL streptomycin for 6 days prior to 
dispersion.  The MIN6 mouse insulinoma beta cell line66 was grown in DMEM medium (Sigma, 
St. Louis, MO) supplemented with 10% FBS, 1 mM sodium pyruvate, and 100 μM 2-
mercaptoethanol.  INS-1 and INS-1-derived 832/1367 rat insulinoma beta cell lines (from C.B. 
Newgard, Duke University, Durham, NC) were grown in RPMI 1640 culture medium (Corning 
Cellgro, Mannassas, VA) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10 mM HEPES, and 0.05 mM 2-mercaptoethanol.  Cell lines and islets were 
maintained and treated at 37°C and 5% CO2. 
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Determination of Endogenous ARAP1 Isoforms  
DNA samples were extracted from 23 primary human pancreatic islet samples using the 
Wizard Genomic DNA Purification Kit (Promega, Madison, WI).  Samples were genotyped using the 
validated TaqMan SNP Genotyping Assay for rs1552224 (Life Technologies, Grand Island, NY) 
according to the manufacturer’s instructions.  Protein lysates were collected using batches of 2000-
4000 islets from five rs1552224 major-allele homozygotes and five heterozygotes.  Islets were lysed 
in ice-cold NP-40 lysis buffer and passed through a syringe equipped with several increasing-gauge 
needles to mechanically break up the islet cells.  Lysates were then clarified at 16,000 x g in a 4°C 
microcentrifuge and protein concentrations were determined using the Pierce BCA Protein Assay 
(Thermo Scientific, Waltham, MA).  Islet cell lysates were flash frozen in a dry ice and ethanol 
bath and stored at -80°C until use.  Western blots were carried out using the NuPAGE Novex 
System coupled with the NuPAGE Novex 3-8% Tris-Acetate Gels and the NuPAGE Novex Tris-
Acetate SDS Running Buffer (Life Technologies) to resolve the higher molecular weight ARAP1 
protein isoforms.  Proteins were transferred onto Invitrolon polyvinylidene difluoride (PVDF) 
membranes using NuPAGE Transfer Buffer (Life Technologies).  Polyclonal antibody to 
ARAP1 (ab5912) was purchased from Abcam (Cambridge, England) and used at a final 
concentration of 1 μg/ml.  After immunodetection of ARAP1, the membrane was washed twice 
for 10 minutes in tris-buffered saline (TBS)-Tween containing 1.5% Glycine, 0.1% SDS, and 1% 
Tween-20 on a shaker to strip primary and secondary antibodies.  Following stripping, the 
membrane was re-probed to detect low molecular weight control proteins.  Antibodies to 
GAPDH (Santa Cruz Biotechnology, Dallas, TX) or β-Actin (Novus Biologicals, Littleton, CO) 
were used at a final concentrations of 1 μg/ml.  Chemiluminescent immunodetection of 
secondary antibodies conjugated with horseradish peroxidase (HRP) was performed using 
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WesternBright Quantam and WesternBright Peroxide (Advansta, Menlo Park, CA).  Membranes 
were developed on film or scanned using LI-COR C-DiGit Blot Scanner and densitometry 
analyses were performed using Image Studio software (LI-COR Biosciences, Lincoln, NE). 
 
Adenoviral Vector Preparation 
Full-length human ARAP1 corresponding to the RefSeq isoform NM_015242 transcribed 
from the ARAP1 P1 promoter was purchased in the Gateway Ultimate ORF pENTR221 entry clone 
backbone (Life Technologies, Grand Island, NY).  Enhanced green fluorescent protein (EGFP) in 
the pENTR4 entry clone backbone was a gift from V. Bautch (University of North Carolina at Chapel 
Hill).  We used site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, 
Agilent, Santa Clara, CA) to change one or both of the previously published18 catalytically active 
arginine residues to lysine residues in each of the ARAP1 GAP domains (positions 333 in the 
ARF-GAP domain and 748 in the RHO-GAP domain of isoform NP_056057, corresponding to 
positions 338 and 753, respectively, of the prior ARAP1 GenBank accession number 
AY049732).  We also changed the terminal stop codon (position 1206) following the final 
coding amino acid, a valine (position 1205) to an alanine to allow translation through the C-
terminal V5 tag that is included in the cytomegalovirus (CMV) promoter-driven Gateway 
pAd/CMV/V5-DEST destination plasmids.  Gateway recombination was performed using LR 
Clonase II (Life Technologies), and recombined plasmids were most efficiently transformed 
using electroporation (GenePulsar II, Biorad, Hercules, CA) into ElectroMAX Stbl4 Competent 
Cells (Life Technologies).  For each construct, several independent plasmid clones were 
selected.  The genotype and fidelity of each cloned ARAP1 variant was verified by sequencing.  
Adenoviral vectors (Ad-CMV) expressing human ARAP1(wt), ARAP1(R333K), 
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ARAP1(R748K), ARAP1(R333K•R748K), ARAP1(wt)-V5, ARAP1(R333K)-V5, 
ARAP1(R748K)-V5, ARAP1 R333K•R748K)-V5, and EGFP were generated from the 
adenoviral plasmids in 293A cells with the ViraPower Adenoviral Expression System according 
to the manufacturer’s instructions (Life Technologies).  At least two independent adenoviral vectors 
were prepared from independent plasmid clones for each ARAP1 variant.  For EGFP, two 
independent adenoviral preparations were generated from the same plasmid clone.  After final 
amplification, all adenoviral vectors were simultaneously titrated using a plaque formation assay and 
then screened for the presence of wild-type replication-competent adenovirus using a supernatant 
rescue assay.95 
 
Adenoviral Vector Transduction 
Intact human islets were incubated overnight in 3 ml of normal growth medium 
containing 10 million plaque-forming units (PFU)/ml adenoviral vector and 10 μg/ml polybrene 
in separate 35 mm non-treated dishes.  Dispersed human islet cells used for glucose-stimulated 
insulin secretion experiments were dissociated from whole islets with a 10 minute incubation in 
Accutase (Life Technologies, Grand Island, NY) in a 37°C water bath, followed by gentle 
pipetting.  The cells were then collected by centrifugation at 1000 rpm for 5 minutes, 
resuspended in complete CMRL human islet culture medium, and seeded at a density of 5,000 
cells per well in non-treated Nunc 96-Well Polystyrene Conical Bottom MicroWell Plates 
(Thermo Scientific, Waltham, MA).  To transduce, dispersed cells were incubated overnight in 
100 μl of normal growth medium containing adenoviral vector at a concentration of 1 million 
PFU/ml.   
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MIN6 cells were seeded at a density of 150,000 cells per well in 24-well plates or 1.5 
million cells per well in 6-well plates and 832/13 cells were seeded at a density of 300,000 cells 
per well in 24-well plates one day prior to transduction.  To transduce, MIN6 cells were 
incubated overnight in normal growth medium containing adenoviral vector at a concentration of 
5 million PFU/ml; 832/13 cells were incubated for one to two hours in normal growth medium 
containing 2.5 million PFU/ml.  After transduction was complete in each tissue or cell type, the 
media were replaced with fresh growth media.  Two days after transduction, consistency of 
transduction efficiency was verified by inspection of EGFP positive cells and islets under an 
inverted fluorescent microscope.  Using the above conditions, over 75% of MIN6, 832/13, and 
dispersed human islet cells were transduced; all intact human islets were transduced, each at 
approximately 50-70%. 
 
Glucose-Stimulated Secretion of Insulin and Proinsulin 
For adenoviral vector transduction of human islets presented in Figure 16, two replicate 
samples of 50 intact islets each were counted into separate Corning Transwell Polycarbonate 
Membrane Cell Culture Inserts (Sigma-Aldrich, St. Louis, MO) fitted in 24-well plates.  Islets 
were rinsed with SAB buffer containing 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 
mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 25.5 mM NaHCO3, and 0.2% BSA, pH 7.2.  After 
rinsing, islets were then pre-incubated in fresh SAB buffer for two hours prior to treatment with 
500 μl of 3 mM or 20 mM glucose for 1 hour.  After each incubation step, islets were spun twice 
for two minutes at 1000 rpm to allow buffer or treatments containing secreted insulin to flow 
through the membrane and into the wells of the plate for removal and collection.  For adenoviral 
vector transduction of human islets presented in Figure 20, four replicate samples of 
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approximately 100 intact islets each were aliquoted into 1.5 ml microcentrifuge tubes, rinsed 
with SAB buffer, and then pre-incubated in 2.5 mM glucose in SAB buffer for one hour.  After 
pre-incubation, islets were first treated with 500 μl of fresh 2.5 mM glucose for one hour and 
then treated with 500 μl of 16.7 mM glucose for one hour.  After each incubation step, islets 
were spun for 5 minutes at 500 rpm, the buffer or treatments were removed or collected from the 
islets via careful pipetting, and the islets were resuspended in the next treatment.  After all 
treatments were complete, islets were rinsed with PBS and then lysed in 40 μl NP-40 lysis buffer 
with protease inhibitor for measurement of total cellular insulin.  Dispersed islet cells were pre-
incubated with 2.5 mM glucose in SAB buffer for one hour prior to treatment with 100 μl of 
fresh 2.5 or 16.7 mM glucose for one hour.  Before and after each incubation step, the “V” 
bottom 96-well plates were spun at 1000 rpm for 5 minutes to reaggregate the islet cells.  Four 
replicate wells per glucose treatment were used for each adenoviral vector transduction.  
Transduced MIN6 and 832/13 cells were rinsed with SAB buffer and pre-incubated in fresh 
buffer for two hours prior to treatment with 500 μl of 3 mM or 20 mM glucose for 2 hours.  
Insulin and proinsulin levels were quantified using human- or rodent-specific enzyme-linked 
immunosorbent assays (ELISA) (Mercodia, Uppsala, Sweden), according to the manufacturer’s 
instructions. 
 
GTPase Activity Assays 
Aliquots of six hundred human islets were used per sample to determine GTPase activity 
levels.  For MIN6, two wells of a 6-well plate, or four wells of a 24-well plate were used per 
sample.  Cell lines and islets were first rinsed with SAB buffer and then incubated in fresh SAB 
buffer for two hours prior to treatment with 20 mM glucose in SAB buffer for precisely 3 
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minutes.  Sample lysates were collected immediately after 3 minutes using G-LISA Activation 
Assay Kit Cell Lysis Buffer and Protease Inhibitor Cocktail according to manufacturer’s 
instructions (Cytoskeleton, Denver, CO).  Sample collection for each cell type was performed in 
two batches in order to quickly and reliably maintain the 3 minute timepoint; batches contained 
one sample each per exogenously expressed construct (i.e., untranduced cells or islets, Ad-
EGFP, and each Ad-ARAP1 variant) to avoid potentially confounding batch effects.  Each of the 
islet lysate samples were also briefly passed through a syringe equipped with increasing-gauge 
needles to mechanically break up the islet cells.  After clarification, lysates were flash frozen in 
liquid nitrogen and stored at -80°C prior to use.  ARF6, CDC42, ARF1, and RHOA activity 
levels were determined using corresponding absorbance-based G-LISA Activation Assay Kits 
according to manufacturer’s instructions (Cytoskeleton), with one deviation: CDC42 samples 
were collected and diluted with the ARF1 or RHOA G-LISA Cell Lysis Buffers due to excessive 
lysing of the beta cell lines using the doubly concentrated CDC42 G-LISA Cell Lysis Buffer.  
Separate aliquots of 400 human islets transduced with each adenoviral vector were rinsed in 
PBS, lysed in NP-40 lysis buffer with Halt Protease Inhibitor Cocktail (Thermo Scientific, 
Waltham, MA), snap-frozen, and reserved for Western blot determination of exogenous ARAP1-
V5 and total endogenous ARF6 levels.  Western blots were performed as described above; 
primary antibody to V5 (Life Technologies, Grand Island, NY) was used at a 1:5,000 dilution.   
 
Immunofluorescence 
Human islets were dispersed in batches of 500-1000 by incubation with 1 ml Trypsin-
EDTA (Sigma, St. Louis, MO) for 5-7 minutes at 37°C and 5% CO2 with occasional passage 
through a 1 ml pipette tip.  Dispersed human islet cells were collected by centrifugation at 500 
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rpm and resuspended in supplemented CMRL human islet culture medium.  The dispersed islet 
cells were seeded onto Nunc Lab-tek II CC2 Chamber Slides (Thermo Scientific, Waltham, MA) 
and incubated in 500 μl human islet culture medium for 48 hours at 37°C and 5% CO2 prior to 
treatment and fixation.  On the day of fixation, the culture media was replaced with 300 μl fresh 
media and islet cells were pre-fixed for 5 minutes through addition of 300 μl 4% 
paraformaldehyde (PFA) directly into the each chamber containing culture media.  The PFA-
media solution was removed and the islet cells were fixed for another 15 minutes in 300 μl 4% 
PFA.  Following fixation, islet cells were rinsed and then washed 3 times for 5 minutes each in 
500 μl PBS.  Islet cells were blocked for 1 hour at room temperature in 500 μl of a PBS solution 
containing 0.1% Triton-X, 1% BSA, and 5% donkey serum.  Antibody incubations were 
performed in 300 μl of a PBS solution containing 0.1% Triton-X and 1% BSA.  Islet cells were 
incubated with primary antibodies overnight at 4°C.  The next day, islet cells were washed 3 
times in PBS and then incubated with secondary antibodies at room temperature for 1 hour in the 
dark.  Islet cells were again washed 3 times in PBS before the chambers were removed and 1.5 
thickness cover slides (Thermo Scientific) were mounted using Prolong Gold Anti-Fade Reagent 
with DAPI (Life Technologies, Grand Island, NY).  Polyclonal antibody to ARAP1 (ab5912) was 
purchased from Abcam (Cambridge, England) and used at a final concentration of 1 μg/ml.  
Antibody to ARF6 (ARF06) was purchased from Cytoskeleton (Denver, CO) and used at a 
dilution of 1:200.  Antibody to insulin (C27C9) was purchased from Cell Signaling Technology 
and used at a dilution of 1:400.  Images were obtained using an Olympus FV1000 Multiphoton 
Confocal microscope and the Olympus FV10-ASW software. 
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Results 
Endogenous Expression of ARAP1 Isoforms in Human Islets 
We examined endogenous expression of ARAP1 protein isoforms in primary human islets 
using Western Blot and a previously published,96 commercially prepared antibody against ARAP1.  
In HepG2 and 293T human cell lines, the strongest band observed (Figure 14, band b) is larger 
than 150 kDa, consistent with the 162 kDa predicted molecular weight of the ARAP1 isoform that 
is expressed from P2 and contains the alternative SAM domain.  In human islets and in mouse and 
rat beta cell lines, we observed a primary band consistent with the 136 kDa predicted molecular 
weight of a shorter ARAP1 isoform expressed from P1 and lacking the SAM domain (Figures 14 
and 15, band a).  In MIN6 cells only, a band is also detected close to 250 kDa.  In the larger set of 
human islet samples, a strong third band was also detected around 200 kDa (Figure 15, band c); 
this band could be an artifact or could correspond to an unannotated isoform of ARAP1. 
To determine if the relative strength of the bands differed by genotype at a T2D risk 
variant, we examined the relative levels of expression of ARAP1 isoforms between the T2D-risk 
increasing and risk decreasing alleles in 10 primary human islet samples: five samples 
homozygous for the C allele and five heterozygous samples at rs11603334.  Relative to the 
consistent GAPDH expression across islet samples, ARAP1 expression was highly variable.  We 
observed no correlation between the levels of relative expression of ARAP1 isoforms and genotype 
(Figure 15).  Specifically, the band intensities relative to GAPDH for any of the ARAP1 isoforms, 
or for all three isoforms combined, were not significantly different between genotypes (all p ≥ .1). 
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Figure 14. Endogenous ARAP1 Isoform Expression across Tissues and Species 
Western blot was used to determine the endogenous levels of ARAP1 isoform expression in primary 
human islets, the HepG2 human hepatocyte cell line, the 293T human embryonic kidney cell line, the 
MIN6 mouse beta cell line and the 832/13 and INS1 rat beta cell lines.  Each lane contained 100 μg 
total lysate. 
 
 
Figure 15. Endogenous Levels of ARAP1 Expression in Human Islet Samples 
Western blot was used to determine the endogenous levels of ARAP1 isoform expression in 10 
primary human islet samples.  Five samples homozygous for the major allele (C) of rs11603334 were 
compared to five heterozygous samples.  Each lane contained 30 μg total lysate. 
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ARAP1 Overexpression Decreases Glucose-Stimulated Proinsulin Secretion in Human Islets 
Our previous study93 suggested that the rs11603334 C allele, associated with increased 
T2D risk and decreased plasma proinsulin levels, may function to increase transcription of ARAP1 
isoforms expressed from the P1 promoter.  Based on this work, we hypothesized that increased 
expression of the ARAP1 RefSeq isoform NP_056057 (136 kDa), corresponding to P1 promoter-
transcribed NM_015242, may lead to decreased glucose-stimulated proinsulin secretion in 
pancreatic beta cells and islets.  Exogenous overexpression by plasmid transfection was inefficient 
in primary islets and highly variable in MIN6 and 832/13 rodent pancreatic beta cell lines (5-50% 
and 1-20%, respectively, data not shown).  Thus, we generated adenoviral vectors expressing 
ARAP1 with or without a 3’ V5 tag under the control of a CMV promoter.  Control adenoviral 
vectors expressing EGFP were able to highly and reproducibly transduce both intact islets and beta 
cells (see Methods).  The ARAP1 adenoviral vectors were used to transduce intact primary human 
islets, dispersed primary human islet cells, and MIN6 and 832/13 cell lines, and the levels of 
proinsulin and insulin secreted in response to treatment with 20 mM glucose were measured.  
Using intact human islets, we observed a decrease in levels of glucose-stimulated proinsulin but 
not insulin secretion from islets expressing exogenous ARAP1 and ARAP1-V5 compared to 
untransduced islets and islets transduced with EGFP (p = .02, Figure 16). 
To determine whether the ARF-GAP or RHO-GAP domain of ARAP1 is responsible for 
regulating proinsulin secretion, we overexpressed ARAP1 constructs that are mutated at one or 
both of the previously described catalytic residues (see Methods) in these domains.  We 
hypothesized that if increased presence and thus activity of an ARAP1 GAP domain was 
responsible for the decrease in proinsulin secretion, the corresponding ARAP1 GAP domain 
mutant should rescue levels of glucose-stimulated proinsulin secretion.  Preliminary results show 
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a trend suggesting that mutating the catalytic residue R333K in the ARAP1 ARF-GAP domain 
may partially rescue glucose-stimulated proinsulin secretion; however, these results were not 
statistically significant (p < .05) (Figure 20).  The R748K mutation in the ARAP1 RHO-GAP 
domain did not appear to rescue levels of glucose-stimulated proinsulin secretion. 
Levels of glucose-stimulated insulin secretion upon ARAP1 and ARAP1-V5 over-
expression did not differ significantly from intact islet controls.  Glucose-stimulated insulin and 
proinsulin levels from dispersed primary human islet cells, MIN6, and 832/13 were not observed to 
be affected by adenoviral vector-mediated over-expression of ARAP1 (Figure 21, and data not 
shown). 
 
        
Figure 16. Proinsulin and Insulin Secretion upon ARAP1 Overexpression in Intact Human 
Islets 
Bar charts show the concentrations of proinsulin and insulin secreted into 500 μl treatment buffer 
from 50 transduced islets after incubation for 1 hour at low (3 mM) and high (20 mM) glucose 
treatments.  Each bar represents the average and standard deviation of two independent preparations 
of adenoviral vector (except untransduced islets); the average of each vector was determined from 
two biological replicate samples.  The p-values were calculated with a two-sided t test.  A 
significance threshold of p < .05 was used; n.s., not significant. 
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ARAP1 Regulates Glucose-Stimulated ARF6 GTPase Activity through its ARF-GAP Domain 
We next hypothesized that increased ARAP1 expression may lower the glucose-
stimulated activity of one or more small GTPases in the beta cell by catalyzing conversion of 
bound GTP to GDP.  To identify GTPases regulated by ARAP1, we overexpressed ARAP1-V5 
in MIN6 determined the levels of GTP-bound ARF6, CDC42, ARF1, and RHOA following 3 
minute treatments with 20 mM glucose.  ARAP1 overexpression did not appear to decrease 
GTP-bound levels of CDC42, ARF1, or RHOA (Figure 17).  For ARF6, we observed a 
reproducible but non-significant trend such that cells with exogenously expressed ARAP1-V5 
contained slightly decreased levels of ARF6-GTP upon glucose stimulation relative to 
untransduced cells and cells transduced with EGFP. 
To validate regulation of ARF6-GTP levels by ARAP1, we repeated the experiment in 
human islets.  We observed that exogenous ARAP1 expression decreased glucose-stimulated 
ARF6-GTP levels (p = .02, Figure 18, left panel).  Expression of the ARAP1 ARF-GAP domain 
mutant, R333K, rescued levels of glucose-stimulated ARF6-GTP (p = .02) while the RHO-GAP 
domain mutant, R748K, did not.  For the ARF-GAP/RHO-GAP double mutant, R333/748K, we 
observed a non-significant trend suggesting rescue.  These data suggest that ARAP1 regulates 
ARF6-GTP levels in human islets through its ARF-GAP domain.  For all transduced islets, the 
total level of endogenous ARF6 were similar (Figure 18, right panel), demonstrating that 
increased ARAP1 expression does not affect the total expression of ARF6. 
To determine whether ARAP1 and ARF6 are located together within the beta cell, we 
assessed cellular localization using immunocytochemistry.  In dispersed primary human islet 
beta cells, ARAP1 and ARF6 partially colocalized together in the cytoplasm (Figure 19A-C).  In 
some instances, these coincident signals also overlapped discrete areas marked by the insulin 
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antibody; however, in most cells, insulin was fairly diffuse (Figure 19D-E).  Taken together with 
the assays of ARF6-GTP levels, these results suggest that ARAP1, through its ARF-GAP 
domain, regulates glucose-stimulated ARF6 activity in primary human islets. 
 
 
Figure 17. Effects of ARAP1 Overexpression on GTP-Bound Levels of Several Small 
GTPases upon Glucose Treatment in MIN6 
Bar charts show the amounts of GTP-bound small GTPase contained in MIN6 cell lysates following 
incubation for 3 minutes in high (20 mM) glucose.  GTP-bound levels were measured as relative 
O.D. units at 490 nm upon completion of the G-LISA GTPase activity assays.  Each bar represents 
the average and standard deviation of two independent preparations of adenoviral vector (except 
untransduced islets).  For each adenoviral vector, an average was first determined from two 
biological replicate samples, which were each technically assayed twice using G-LISA.  The entire 
experiment was carried out twice for ARF6 and CDC42, and once for ARF1 and RHOA. 
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Figure 18. ARAP1 Regulates ARF6 Activity in Human Islets through its ARF-GAP 
Domain 
The bar chart (left) shows the relative amounts of ARF6-GTP contained in lysate from 600 
transduced islets following incubation for 3 minutes in high (20 mM) glucose.  GTP-bound levels 
were measured as relative O.D. units at 490 nm upon completion of the G-LISA GTPase activity 
assays.  Each bar represents the average and standard deviation of two independent preparations of 
adenoviral vector (except untransduced islets).  For each adenoviral vector, an average was first 
determined from two biological replicate samples, which were each technically assayed twice using 
G-LISA.  The ARAP1 R333K mutation alters the catalytic residue in the ARF-GAP domain; the 
R748K mutation alters the catalytic residue in the RHO-GAP domain.  The p-values were calculated 
with a one-sided t test.  A significance threshold of p < .05 was used; n.s., not significant.  The 
Western blot (right) shows relative islet levels of exogenously expressed ARAP1-V5 and levels of 
total endogenous ARF6 and endogenous GAPDH.  Each lane contained 10 μg total lysate from islets 
transduced with independent preparations of adenoviral vector. 
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Figure 19. ARAP1 and ARF6 Partially Colocalize in the Cytoplasm in Human Beta Cells 
Immunocytochemistry was used to visualize localization of endogenous ARAP1 and ARF6 in 
dispersed primary human beta cells.  Each frame above (A-F) shows two independently captured 
images.  Example areas of ARAP1 and ARF6 colocalization are highlighted with white arrows. 
 
Discussion 
In this study, we demonstrate that ARAP1 may play a functional role at the locus associated 
with type 2 diabetes and proinsulin on 11q13.4.  We characterized localization and isoform 
expression of ARAP1 in the human pancreatic islet and showed that the 136 kDa ARAP1 RefSeq 
isoform NP_056057 can regulate glucose-stimulated proinsulin secretion in intact primary islets.  We 
also identified this ARAP1 isoform as a GAP for ARF6 in islets, and showed that its ability to 
regulate glucose-stimulated ARF6-GTP levels is dependent on the activity of its ARF-GAP domain. 
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Upon examination of ARAP1 protein isoforms in human islets using an antibody targeting 
the C-terminal end of ARAP1, we observed two to three major bands.  Two of these bands match 
predicted sizes of ARAP1 protein isoforms in the RefSeq database that start with exons at the P1 
(136 kDa) and P2 (162 kDa) promoters.  The smaller band labeled ‘a’ was a primary one in human 
islets as well as in MIN6 mouse and 832/13 and INS1 rat beta cell lines.  This band may represent 
either or both of the similar ARAP1 protein isoforms NP_056057 and NP_001128662, which differ 
by two codons containing 72 amino acids, or about 8 kDa.  The larger band labeled ‘b’, which may 
represent the ARAP1 protein isoform NP_001035207, was most important in human HepG2 
hepatocyte and in HEK293T embryonic kidney cells, suggesting different regulation of isoform use 
across tissues. 
The identity of the third band that we observed around 200 kDa is unknown; however, it was 
strong in 6 of 10 human islet samples we examined.  This 200 kDa band may be an experimental 
artifact, or may represent a closely related protein detected by the ARAP1 antibody.  Alternatively, 
other unannotated isoforms of ARAP1 may exist.  Two other human genome references, available on 
the University of California Santa Cruz (UCSC) Genome Browser and from the GENCODE97 
consortium annotate a predicted non-RefSeq ARAP1 isoform that is transcribed from the STARD10 
promoter on the same strand as STARD10, but contains no STARD10 coding exons.  The molecular 
weight of this isoform is predicted to be only 161 kDa (UCSC, uc001osv.3; GENCODE, 
ENST00000359373.5), so this predicted isoform does not seem to explain the origin of a 200 kDa 
protein.  Noting that ARAP1 may also be transcribed from the STARD10 promoter and that the 
predicted molecular weight of STARD10 is 33 kDa, we hypothesize that a 200 kDa band, if 
confirmed to exist, may represent a potential STARD10-ARAP1 fusion protein containing the full 
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sequence of both genes, which would have a theoretical size of 195 kDa.  Additional experiments 
would be required to determine the existence of any unannotated ARAP1 protein isoforms. 
We did not observe a significant difference in the relative levels of ARAP1 136 kDa isoform 
expression between T2D risk-increasing and T2D risk-decreasing genotypes.  Our analysis of only 
10 islet samples may be underpowered to detect the small predicted difference in expression of the 
shorter ARAP1 isoform across genotypes based on our previous allelic imbalance findings in human 
islet mRNA.  However, the intensities of ARAP1 isoform expression relative to GAPDH differed 
substantially across samples, suggesting that other factors may influence ARAP1 expression or 
relative isoform use in human islets. 
In support of our previous report implicating a possible role for increased expression of 
ARAP1 in decreased fasting proinsulin levels, we provide here the first experimental evidence 
demonstrating that ARAP1 (NP_056057) over-expression decreases the amount of proinsulin 
secreted by intact primary human pancreatic islets in response to a 1 hour glucose treatment.  
Preliminary findings also suggest that ARAP1 might exert this effect through the activity of its ARF-
GAP domain, although our results were not statistically significant (p > .05); this experiment is worth 
repeating when islet resources allow.  We did not observe ARAP1 over-expression to influence 
glucose-stimulated proinsulin secretion in MIN6 or 832/13 rodent pancreatic beta cell lines, nor did 
we observe an effect in dispersed primary human islets.  These results suggest that ARAP1 may 
regulate proinsulin secretion through a pathway mediated by cell-to-cell interactions in the islet, 
highlighting the importance of examining beta cell function in the context of intact islets.  
Alternatively, species- and/or cell-line differences may explain the lack of effect in MIN6 and 
832/13, and possible adenoviral vector toxicity to freshly dispersed islet cells may have obscured our 
ability to observe genetic effects that are expected to be more subtle.  Since proinsulin is secreted in 
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small amounts along with mature insulin from exocytosed insulin secretory granules in the beta cell, 
we hypothesized that ARAP1 over-expression may also decrease insulin secretion in intact primary 
human islets.  We did not observe a clear effect of ARAP1 over-expression on 1 hour glucose-
stimulated insulin secretion; however, further investigation is warranted. 
We show that adenoviral vector-mediated ARAP1 (NP_056057) over-expression decreases 
glucose-stimulated ARF6-GTP levels in human pancreatic islets and demonstrate that this effect is 
dependent on the activity of the ARAP1 ARF-GAP, but not the RHO-GAP, domain.  Lending further 
support, we observed that ARAP1 and ARF6 partially colocalize together in the cytoplasm of 
dispersed human pancreatic beta cells.  ARAP1 has been identified as a GAP for ARF6 in vitro18 and 
in BHK cells,32 and we now validate that it has GAP activity for ARF6 in human islets.  Given the 
possibility that ARAP1 may also regulate glucose-stimulated proinsulin secretion through its ARF-
GAP domain, our results suggest that ARF6 could be one GTPase through which ARAP1 may act to 
regulate proinsulin secretion; this would implicate a potential role for ARF6 in proinsulin secretion as 
well.  A full investigation of ARAP1’s activity for all known ARF- and RHO-GTPases, combined 
with a set of experiments investigating the proinsulin-specific effects of knocking down ARF6 or 
decreasing the glucose-stimulated activity of ARF6 may provide further insight. 
This work contributes to understanding of ARAP1’s biological role as a functional 
candidate gene in the pancreatic islet without excluding roles for ARAP1 in other T2D-relevent 
tissues or roles for other genes at the 11q13.4 locus.  Given that expression of the ‘long’ ARAP1 
SAM domain-containing isoform is highly preferred in HEPG2 cells, a mechanism that leads to low 
but aberrant expression of the potentially more active, SAM domain-lacking, ‘shorter’ ARAP1 
isoform(s) in human hepatocytes may be biologically disruptive to liver-specific pathways.  Possible 
involvement of a T2D-associated gene in biological pathways related to both the pancreas and the 
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liver is not without precedent: this may be the case with TCF7L2.98  In the pancreas and islet, 
STARD10 (StAR-related lipid transfer domain containing 10) is another strongly expressed gene at 
the T2D-associated 11q13.4 locus, making it another logical candidate worth examining for a 
possible role in insulin secretion. 
 
Supplemental Figures 
 
 
Figure 20. Glucose-Stimulated Proinsulin Secretion in Islets Transduced with ARAP1-
Expressing Adenoviral Vectors 
Bar charts show the levels of secreted proinsulin, normalized to total islet lysate insulin levels, from 
100 transduced islets after incubation for 1 hour at high (16.7 mM) glucose.  Each bar represents the 
average and standard deviation of two independent preparations of adenoviral vector (except 
untransduced islets).  For each adenoviral vector, an average was first determined from four islet 
samples.  The ARAP1 R333K mutation alters the catalytic residue in the ARF-GAP domain; the 
R748K mutation alters the catalytic residue in the RHO-GAP domain.  The p-values were calculated 
with a one-sided t test; n.s., p > 0.1. 
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Figure 21. Glucose-Stimulated Proinsulin and Insulin Secretion in Dispersed Primary 
Human Islet Cells Transduced with Wild Type and Mutant ARAP1 
Bar charts show the concentrations of proinsulin and insulin secreted into 50 μl treatment buffer from 
5,000 dispersed islet cells after incubation for 1 hour at low (2.5 mM) and high (16.7 mM) glucose 
treatments.  Two sets of islet cells were used; the results for the first set appear in A-B and the results 
for the second set appear in C-D.  Each bar represents the average and standard deviation of two 
independent preparations of adenoviral vector (except untransduced islets).  For each adenoviral 
vector, an average was first determined from four dispersed islet cell samples.  The ARAP1 R333K 
mutation alters the catalytic residue in the ARF-GAP domain; the R748K mutation alters the catalytic 
residue in the RHO-GAP domain. 
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CHAPTER 4: DISCUSSION 
 
 In this dissertation, I investigated and described functional molecular and biological 
mechanisms that may underlie the genome-wide association of the ARAP1 locus with proinsulin 
levels and T2D.  Here, I discuss the implications of these results, consider the possible role of 
increased ARAP1 expression in T2D risk, and outline other potential mechanisms. 
 The rs11603334-C allele at the ARAP1 locus is robustly associated with decreased fasting 
plasma proinsulin levels (p = 3.2 x 10-102, n > 19,000)2 but only nominally associated with levels of 
decreased plasma insulin during an OGTT (p = 0.001, n = 5,529).3  Recent results also show a very 
strong association between the ARAP1-increasing,93 rs11603334-C allele and decreased plasma 
proinsulin levels in human subjects 30 minutes after introduction of oral glucose (p = 4.6 x 10-54,  
n ~ 8,600 Finnish males, unpublished data, Markku Laakso, Johanna Kuusisto, Alena Stančáková, 
Henna Cederberg).  Consistent with these dramatically different strengths of association, we 
observed that experimental overexpression of ARAP1 in cultured intact human pancreatic islets led 
to decreased 1 hour glucose-stimulated proinsulin secretion, but we did not find a significant effect of 
ARAP1 overexpression on 1 hour glucose-stimulated insulin secretion. 
 In addition to the striking disparity between the strength of the proinsulin and insulin 
associations, the directions of effect for the T2D and plasma proinsulin associations at the ARAP1 
locus differ from other GWAS loci in an unconventional way: the allele associated with decreased 
measures of insulin secretion and increased risk of T2D (rs11603334-C) is associated with decreased 
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plasma proinsulin levels.  At the TCF7L2, SLC30A8, and VPS13C loci, the T2D risk-increasing 
alleles are associated with increased proinsulin levels and are thought to interfere with insulin 
processing in the beta cell such that higher amounts of proinsulin are secreted in place of insulin.2  
The ARAP1 locus phenotype associations also stand in contrast to the epidemiological observation 
that elevated plasma proinsulin associates with an increased risk of T2D.99  To our knowledge, 
ARAP1 is the only GWAS locus associated with both T2D and proinsulin that exhibits this unusual 
direction of effect. 
 We and others2 have proposed that the biological mechanisms underlying these ARAP1 locus 
associations might contribute to an overall defect in insulin packaging, trafficking, or exocytosis, 
such that the release of all forms of insulin hormone would be impaired.  Such a defect would 
logically be expected to contribute to increased T2D susceptibility, as it would directly affect the 
ability of the beta cell to secrete insulin.  We initially hypothesized that, in cultured β-cells or islets, 
glucose-stimulated secretion of both insulin and proinsulin may be decreased by experimentally 
increasing ARAP1 expression, postulating that the associations for fasting and OGTT proinsulin 
could be stronger than those of insulin as a simple consequence of proinsulin’s longer half-life in the 
bloodstream.  In this model, we expected to observe statistically significant decreases in both 
proinsulin and insulin secretion by islets ex vivo into a cell culture treatment buffer that has no ability 
to clear insulin.  Further, since imminently exocytosing insulin granules contain much more mature 
insulin than immature proinsulin, the net loss in secreted insulin arising from potential global 
trafficking or exocytosis defects might be predicted to be even more apparent than that of secreted 
proinsulin.  But, when we overexpressed ARAP1 in cultured intact islets, we observed a significant 
decrease in secreted proinsulin levels only. 
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 What does it mean that we did not observe ARAP1 overexpression to also affect insulin 
secretion in intact islets?  First, the experiment is worth repeating in additional human islet samples 
in order to validate this negative finding. 
 One alternative hypothesis may be that increased ARAP1 expression could cause a short 
delay in plasma membrane recruitment and/or exocytosis for some insulin secretory granules.  This 
delay might afford increased opportunity for late proinsulin-to-insulin processing within the granules; 
and a consequence of this could be that, over a cumulative period of 30 minutes or longer, relative 
proinsulin levels may be decreased to a greater extent than insulin.  In this model, proinsulin 
secretion would be decreased due to both the delay and the processing; insulin secretion would be 
decreased early on by the delay, but subsequently recover to a certain extent from increased 
processing.  It is unclear how long such a delay would have to be and what proportion of insulin 
granules would need to be affected to demonstrate these disparate phenotypes; too long of a delay or 
the involvement of too many insulin granules would greatly affect insulin secretion as well as 
proinsulin; the kinetics may be delicately balanced.  Measuring insulin and proinsulin secretion at 
earlier, more precise time points in the clinic and in cultured human islets ex vivo using islet 
perfusion studies may help validate a hypothesis implicating delayed granule exocytosis.  On the 
cellular level, the kinetics of exocytosis could be examined and quantified more precisely using 
measurements of beta cell plasma membrane capacitance.  As with a theoretical global defect in 
insulin granule trafficking or exocytosis, a hypothetical persistent delay in insulin and proinsulin 
secretion immediately upon feeding, when glucose levels are highest, would subject the body to 
recurrent, slightly longer periods of elevated glucose exposures and could also conceivably 
contribute to risk of developing T2D, especially for insulin-resistant individuals. 
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 In human pancreatic islets, we also discovered that increased ARAP1 expression decreases 
the levels of glucose-stimulated ARF6-GTP.  We found that the regulation of ARF6 by ARAP1 is 
dependent on ARAP1 ARF-GAP domain activity and noted a non-significant trend suggesting that 
ARAP1 regulation of proinsulin secretion might also be dependent on the ARF-GAP domain.  While 
ARAP1 regulation of other GTPases in the human islet has not been ruled out, the above findings 
lead us to postulate that ARAP1 could partially influence proinsulin secretion through regulation of 
ARF6. 
 A regulatory role of ARF6 in proinsulin secretion has not yet been specifically demonstrated; 
however, other groups have reported that MIN641 and 832/1340 cells expressing a dominant negative, 
non-GTP binding ARF6(T27N) mutant have reduced glucose-stimulated insulin secretion.  
Examining the effects of this ARF6(T27N) mutant, or the effects of ARF6 knock-down, on glucose-
stimulated proinsulin levels would help determine if it is conceivable that ARAP1 could regulate 
proinsulin secretion through ARF6. 
 ARF6 has been previously linked to late-stage exocytosis, suggesting that an ARAP1/ARF6-
mediated biological mechanism could be compatible with the ‘delay’ hypothesis.  In PC12 
neuroendocrine cells, ARF6 activity regulates K+-stimulated growth hormone secretion through its 
ability to activate downstream effector phospholipase D1 (PLD1),100–102 an enzyme that is reported 
to stimulate exocytosis by generating ‘fusogenic’ lipid second messenger phosphatidic acid (PA) 
from phosphatidylcholine, which may aid in granule fusion with the plasma membrane.103  As others 
have previously proposed94 in light of evidence in MIN6 cells that PLD1 activity is required for 
proper glucose stimulated insulin secretion,104 ARF6-GTP may regulate late-stage insulin granule 
exocytosis through its activation of PLD1.  As an upstream regulator of ARF6, ARAP1 may 
modulate this pathway (Figure 22).  Changes in PLD activity upon ARAP1 overexpression could be 
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determined by using a radiolabeled phospholipid biochemical assay such as 
transphosphatidylation105,106 or by using a chemically coupled commercial assay, such as the Amplex 
Red Phospholipase D Assay Kit (Life Technologies, Grand Island, NY).  
 
 
Figure 22. Proposed Model for ARAP1 regulation of Insulin Granule Exocytosis 
Increased ARAP1 expression decreases glucose-stimulated ARF6-GTP levels and 1 hour 
proinsulin but not insulin secretion in human islets, suggesting a functional role for ARAP1 in 
regulating the kinetics of insulin granule exocytosis, possibly through an ARF6/PLD1/PA 
pathway. 
 
 A philosophical counterargument to our proposed ARAP1/ARF6-mediated ‘delay’ 
hypothesis arises when we consider that we did not observe a significant effect of ARAP1 
overexpression on glucose-stimulated insulin secretion in human pancreatic islets, even though 
disrupting ARF6-GTP activity has been shown to decrease glucose-stimulated insulin secretion in 
MIN641 and 832/13.40  Species differences in the nature of GTPase regulation by ARAP1 may be 
important considerations here, as we did not observe ARAP1 overexpression to decrease glucose-
stimulated proinsulin or insulin secretion in MIN6 or 832/13.  Also importantly, in the previous 
studies, ARF6 siRNA knockdown or overexpression of a dominant negative, non-GTP binding 
ARF6(T27N) mutant were used to show an effect.  Relative to increased presence of ARAP1, our 
proposed ARF6 GAP, these ARF6-specific disruptions are fairly severe and mechanistically more 
proximal; they may be expected to affect the recruitment and/or exocytosis of a majority of insulin 
secretory granules.  As discussed above, in the ‘delay’ hypothesis, we would anticipate that the 
involvement of many insulin granules would greatly affect insulin secretion as well as proinsulin.  
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Alternatively, increased ARAP1 expression may delay insulin granule recruitment or exocytosis 
through regulation of another small GTPase.  ARAP1’s ability to help catalyze GTP to GDP 
conversion for additional GTPases could be tested using G-LISA activity assays, if human islet 
resources allow. 
 There could also be more than one biological mechanism relating increased ARAP1 
expression to plasma proinsulin, plasma insulin, and/or T2D susceptibility.  In the islet, ARF6, or 
another GTPase, could be found to mediate a potential effect of increased ARAP1 expression on 
secretion of proinsulin in the minor constitutive pathway,107 distinct from the role of ARF6 on 
glucose-stimulated insulin secretion.  Meanwhile, ARAP1 could influence T2D risk by decreasing 
levels of one or more GTP-bound GTPases in other tissues.  CDC42, for example has been 
demonstrated to play a role in insulin-stimulated glucose transporter 4 (GLUT4) translocation to 
the plasma membrane in 3T3-L1 mouse adipocytes.43  Defects in the GLUT4 translocation/glucose 
uptake part of the insulin signaling pathway could contribute to insulin resistance.  Examining the 
ability of ARAP1 to regulate levels of CDC42-GTP and other GTP-bound GTPases and measuring 
the effects of increased ARAP1 expression on insulin-stimulated GLUT4 translocation and glucose 
uptake in adipocytes, hepatocytes, and skeletal muscle cells may shed light on a potential role for 
ARAP1 in insulin resistance.  Additionally, whole-organism ARAP1 knockout, transgenic, or ARAP1 
locus humanized mouse models would allow ascertainment of the effects of altered ARAP1 
expression across T2D-relevant tissues an in conjunction with a diabetogenic diet. 
We cannot rule out possible roles for other isoforms of ARAP1 or for other genes at the 
ARAP1 locus in influencing proinsulin levels or T2D risk.  We chose to investigate the full length 
ARAP1 protein isoform translated from P1 promoter-transcribed mRNA, NP_056057, rather than its 
closely related alternative ARAP1 protein isoform, NP_001128662, which is predicted to contain 
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modified ARF-GAP and C-terminal PH domains due to two missing in-frame exons in the mRNA 
sequence.  The results from our first study examining a possible molecular mechanism underlying 
the ARAP1 locus did not determine that mRNA transcript level for the ‘long’ SAM-domain 
containing isoform of ARAP1 is necessarily regulated by rs11603334; we did not test the effects of 
its altered expression in our follow-up study.  The ‘long’ isoform of ARAP1 does not catalyze ARF6-
GTP hydrolysis in BHK cells,32 suggesting that the SAM domain may function as a negative 
regulator of ARAP1 ARF-GAP activity.  For this reason, it seems less likely that this isoform would 
play as important a role in ARAP1-regulated phenotypes that are dependent on activity of the ARF-
GAP domain, and in particular those mediated by ARF6.  All of the other genes within the 
association signal are similarly understudied; none have yet been clearly implicated in T2D to date.  
STARD10 (StAR-related lipid transfer domain containing 10) binds and transfers phospholipids 
between membranes.19  The particularly strong expression of STARD10 in pancreas and islets makes 
it another logical candidate worth examining for a possible role in insulin granule exocytosis. 
For the vast majority of the thousands of complex-trait loci identified through GWAS, the 
molecular and biological mechanisms underlying these associations are yet to be determined.  
Investigation of the molecular mechanisms at these loci will help to identify the target genes and 
establish the direction of their regulation in individuals at increased risk of disease.  Exploration of 
the biological mechanisms will help us discover novel pathways involved in disease pathology that 
could be used to develop therapies and interventions to advance human health. 
Post-GWAS functional investigation presents a multifaceted challenge: many complex trait 
loci consist of dozens of non-coding variants spread across several genes that may all be 
understudied novel candidates for the associated trait.  In this set of research studies, we have 
modeled one way to identify the functional variant(s) and gene(s) and we begin to elucidate the 
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causal molecular and biological mechanisms that explain the trait associations.  Integration of the 
available statistical, clinical, and bioinformatic research data with a thorough understanding of the 
available literature is critical to increasing the quality of hypotheses that can be experimentally tested.  
Unlike many important statistical and bioinformatic research efforts that help identify new genetic 
‘leads’ and contribute to building good hypotheses, well-done functional studies that identify and 
investigate the biological role of these candidate genes require iterative hypothesis generation and 
experimental testing.  This hypothesis-driven research is highly time-consuming and expensive.  To 
increase our collective scientific capacity to translate the investment we have made in GWAS into 
developing therapies and interventions, more attention, resources, and funding need to be applied to 
this crucial but rate-limiting step. 
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